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Abstract 
 
A significant challenge of the 21st century is to curb the growing threat of drug-
resistant infectious diseases. There is an undeniable need to discover new, safe 
and effective drugs with novel mechanisms of action to combat this problem. A 
study of drugs from the past 25 years showed that natural products account for 
approximately 75% of new anti-infective drugs, either as new agents or analogs 
based upon their structure. Unfortunately, Big Pharma has cut back 
tremendously in natural products research in part due to the frustrating obstacle 
of frequent rediscovery of compounds. Fungi in particular are difficult to work with 
in that they do not always produce the same variety and quantities of secondary 
metabolites under laboratory conditions. Epigenetic modifications such as DNA 
methlytransferase or histone deacetylase inhibition can reverse this effect by 
activating silenced genes leading to the genesis of novel secondary metabolites. 
The work presented herein is a study of the isolation and characterization of anti-
infective compounds from Floridian mangrove endophytes. Epigenetic 
modifications were explored in order to increase the production of secondary 
metabolites as well as for the purpose of generating new analogs not found in 
controls. Moreover, structure activity relationship studies were performed in order 
to maximize the anti-malarial and antibiotic activity of cytosporone E. 
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Chapter One. Fungal natural products as medicaments 
 
1.1. The threat of drug-resistant infectious diseases 
1.1.1. Malaria  
 
A significant challenge of the 21st century has been to curtail the growing health 
threat stemming from drug-resistant infectious diseases. Globally, one of the 
most prominent and deadly infectious diseases is malaria with an estimated one 
million fatalities per year. Since the 1957 discovery of the first case of 
chloroquine (1.1) resistance originating from the Thai-Cambodian border, 1 
scientists have struggled to discover alternative treatments for malaria. The 
resistance spread throughout the world in just two decades (Figure 1.1) and as a 
result chloroquine was replaced by the combination therapy of sulphadoxine (1.2) 
and pyrimethamine (1.3) (Fansidar) in the 1970s. 
 
Unfortunately, there was evidence early on that, again, at the Thai-Cambodian 
border the parasites developed a resistance to the drugs.2 Developed in the 
1970s, the drug mefloquine (1.4), like chloroquine a quinoline derivative, became 
the treatment of choice in the mid 1980s. However by the end of the decade 
Plasmodium falciparum parasites had become resistant to it as well.3 
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Figure 1.1. "Spread of Drug-Resistant Malaria" from Public Health Biology. Available at: 
http://ocw.jhsph.edu. Copyright © Johns Hopkins Bloomberg School of Public Health. Creative 
Commons BY-NC-SA. 
 
                                                                
                            1.1: chloroquine                                                     1.2: sulfadoxine 
 
                                       
                     1.3: pyrimethamine                                               1.4: mefloquine (racemic) 
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Artemisinin (1.5), a very potent antimalarial natural product originating from 
China, became the next and to date most effective treatment option. Due to poor 
solubility it was synthetically modified to offer two analogs artesunate (1.6) (water 
soluble) and artemether (1.7) (lipid soluble). The World Health Organization 
(WHO) encouraged the use of these artemisinin-based compounds in 
combination therapy (ACT) with others in order to prevent the development of 
resistance by the parasites. 
                  
   1.5: artemisinin                                        1.6: artesunate                           1.7: artemether 
 
Alas, just as incidences of death declined about 30% (since last decade),4 as of 
2006 strains of P. falciparum emerging from western Cambodia are resistant to 
artemisinin drugs.5 This could create a public health disaster if spread to the 
African continent in the same way chloroquine-resistance did in the 1980s. What 
makes this Thai-Cambodian border the epicenter of resistance? Ongoing 
research suggests that the P. falciparum parasite endemic to that region is highly 
adaptable and is able to develop resistance quicker than in other areas. For 
example, it was observed that changes in the phenotype of the artemisinin-
resistant parasites led to a stage of dormancy when in contact with ACT drugs.6 
During this stage the parasites are protected and when the drugs clear the body, 
recrudesce; this could very well be one of the ways the parasites resist ACT.7 
O
O
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H O
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H
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H
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1.1.2. Methicillin-Resistant Staphylococcus aureus 
 
In the realm of drug-resistant infectious diseases, Methicillin-Resistant 
Staphylococcus aureus (MRSA) stands out as the most notorious in the United 
States, with an estimated 18,650 deaths per year.8 With the discovery of 
penicillin (1.8) in the 1940s, the treatment of S. aureus infections was possible 
and even routine in hospitals. However, over the decade into the 1950s 
S. aureus developed resistance to the drug.9 To counter these newly resistant 
strains, methicillin (1.9), an analog of penicillin was brought into play in 1959. 
Just two years later, strains resistant to methicillin were reported in laboratory 
tests,10 though it wasn’t until 1968 that the first human cases were discovered.11 
These strains were found to be resistant to the entire class of beta-lactams such 
as penicillin, amoxicillin (1.10), oxacillin (1.11) and methicillin, thus the genesis 
MRSA.  
               
                         1.8: penicillin G                                                       1.9: methicillin         
N
S
O
OH
O
H
N
O N
S
O
OH
O
H
N
O
OCH3
OCH3
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                         1.10: amoxicillin                                                             1.11: oxacillin 
 
Linezolid (1.12), an oxazolidinone discovered in the 1990s was effective against 
drug-resistant bacteria but by 2001 clinical isolates of MRSA were found to also 
resist it.12 Furthermore, it has been speculated that during the 2001 bioterrorist 
threat of anthrax,13 the overuse of ciprofloxacin (1.13) allowed common 
pathogenic microbes, including S. aureus, to develop resistance to 
fluoroquinolones.14 By 2003 a new drug, daptomycin (1.14) was approved by the 
U.S. Food and Drug Administration (FDA) to treat patients afflicted with MRSA 
and other antibiotic-resistant bacteria but it only took one year to find a clinical 
case of daptomycin-resistant strain of MRSA.15  
              
                         1.12: linezoid                                                             1.13: ciprofloxacin 
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1.14: daptomycin 
 
 
 
Vancomycin (1.15), since its fast track approval by FDA in 1958 has been to date 
the most effective drug to combat MRSA and, rightfully so, has been reserved at 
a “last resort” drug in medical treatment. Sadly, in 1997 cases of vancomycin-
resistant S. aureus (VRSA) strains became apparent.16 Though rare, VRSA has 
the potential to be a serious public health problem. Further compounding the 
threat is that recent research has shown that Vancomycin-Resistant Enterococci 
(VRE) bacteria are able to pass the genes to others including S. aureus.17 
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1.15: vancomycin 
1.1.3. Natural products inspire hope 
 
There is a growing need to discover new, safe and effective drugs with novel 
mechanisms of action to combat this threat of drug resistance. A study in 2007 of 
drugs currently on the market showed that natural products account for 
approximately 75% of new anti-infective drugs, either as new agents or 
compounds based upon a natural product scaffold.18 This statistic emphasizes 
the importance of natural products in the discovery of new bioactive compounds. 
Artemisinin, the potent antimalarial, was discovered in China from leaves of 
Artemisia annua.19 Erythromycin, the broad-spectrum antibiotic became a key 
relief for people who were allergic to penicillin and was isolated from a strain of 
the actinomycete Saccharopolyspora erythraea indigenous of the Philippines.20 
Streptomycin (1.16), the first antibiotic agent to combat tuberculosis21 was 
isolated from the actinobacterium Streptomyces griseus.22 Paclitaxel (1.17), the 
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revolutionary mitotic inhibitor used in cancer chemotherapy  was isolated from 
the bark of Taxus brevifolia from Washington State.23  All of these and many 
more natural products are or inspired landmark drugs in their respective fields, 
stressing the importance of chemical mining in nature. 
 
    
                        1.16: streptomycin                                                  1:17: paclitaxel 
 
1.2. The all important fungi 
1.2.1. History of human uses of fungi 
 
Fungi are eukaryotic organisms that include mushrooms, yeasts, molds, rusts, 
smuts, puffballs, truffles and some lesser-known types. While only about 100,000 
species of fungi have been described,24 it is estimated that there are far more 
species existing. In 1991, Hawksworth estimated as many as 1.5 million 
species.25 However, thanks to advances in high-throughput sequencing, a more 
recent study estimated that the number is closer to 5.1 million.26 We have just 
begun to explore this Kingdom! Throughout history mankind has used fungi in a 
variety of applications. First and foremost, fungi have been cultivated or collected 
in the wild as food such as Agaricus bisporus, commonly known as the white 
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button mushroom, Cantharellus cibarius, the elusive chanterelle, and 
Tuber melanosporum, the exquisite truffle. Some have been used in the 
preparation of foods such as Penicillium roqueforti, which imparts the unique 
flavor in blue cheese; others such as the Saccharomyces yeasts, have been 
used as leavening agents in bread or for ethanol and carbon dioxide production 
in beer making. In addition to food, entomopathogenic fungi such as 
Beauveria bassiana have been used as a form of biopesticide. A notable 
example published recently by Thomas described a novel technique in reducing 
the spread of malaria by spraying a suspension of B. bassiana, a fungus 
harmless to humans, on walls and nets in afflicted areas to kill potentially infected 
mosquitoes.27 
 
Fungi have also been used as bioremediation agents. White-rot fungi, mostly 
from the Basidiomycetes phylum, have been show to greatly decompose or 
sequester pesticides, hydrocarbons and toxic industrial wastes.28 Finally, and 
most relevant to this research, are the therapeutic uses of fungi. Mushrooms 
such as Ganoderma lucidumI, the Lingzhi mushroom, Inonotus obliquus, the 
chaga mushroom, and Grifola frondosa, or commonly known as the hen-of-the-
woods mushroom, have a long history in folk medicine and touted to have anti-
cancer properties, immune system up-regulation, antioxidant activity, liver-
protecting properties, antibacterial and antifungal properties, reducing blood 
cholesterol and promoting psychedelic experiences.29 
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Modern scientific techniques have been employed to isolate and identify the 
metabolites responsible for those historic uses. Fungi produce a great variety of 
unique natural products ranging from peptides to alkaloids to terpenes and 
polyketides.30 For example, the blood-tooth fungus, Hydnellum diabolus, 
produces a characteristic red pigment identified as atromentin (1.18), a potent 
anticoagulant that was shown to be as effective as the drug heparin (1.19).31 
Aspergillus terreus produces the well known and original statin, Coenzyme A 
reductase inhibitor lovastatin (1.20).32 
 
                 
                        1.18: atromentin                                                        1:19: heparin 
 
1.20: lovastatin 
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Psilocybe mexicana mushrooms, originally consumed by Mayans to induce 
psychedelic religious experiences, produce two highly psychoactive compounds 
psilocybin (1.21) and psilocin (1.22).33 
 
                       
                             1.21: psilocybin                                                   1.22: psilocin 
 
Finally, the wonder drug of the 1940s, penicillin, was isolated from the mold 
Penicillium notatum and has been one of the most important antibiotics to date.34 
Many of these secondary metabolites discussed as well as others such as the 
toxins alfatoxin (1.23) and muscimol (1.24) are exclusive to fungi, thus it is 
imperative to continue to investigate this Kingdom.  
 
                              
                              1.23: alfatoxin                                                         1.24: muscimol 
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1.2.2. Endophytic fungi and their advantage 
 
Endophytes can be described as microorganisms that colonize and live within the 
cells of plants (Figure 1.2) without producing negative effects on the host.35 The 
relationship is generally considered to be symbiotic; the plant serves as a stable 
environment and source of nutrients while the endophyte provides a chemical 
defense system for the host against pathogens, insects or herbivores.36 One of 
the most studied examples of endophytes is ryegrass colonized with the 
Neotyphodium sp. fungus. The process became commercialized in the 1990s 
because the endophyte produced alkaloids that were effective insecticides 
fending off pests.37 In addition it was shown that the endophytes helped the grass 
resist diseases, drought, and extreme weather (Figure 1.3).  
 
          
Figure 1.2. Endophyte 
mycelium in leaf tissue. Photo 
by Nick Hill, USDA: ARS 
Figure 1.3. The grass on the right is colonized with 
Neotyphodium sp, while the grass on the left is not. Alison 
Popay. Te Ara - the Encyclopedia of New Zealand. 
 
Endophytes, though rather unstudied, have been reported to produce novel 
antibiotics, anti-cancer drugs, and insecticides.38 Furthermore, an important 
advantage of endophytes to the pharmaceutical field is their ability to produce 
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bioactive metabolites previously only reported from their host. The most 
important example of this phenomenon is the cancer drug paclitaxel. The 
diterpenoid is isolated in rather low yields (0.4 g/kg)39 from the bark of 
T. brevifolia and unfortunately this inefficient and wasteful process destroys the 
host tree. Fortunately, in 1993 Stierle and co-workers discovered an endophytic 
fungus of the pacific yew tree that was a paclitaxel producer.40 This finding 
brought a much needed alternative to mass production for pharmaceutical use as 
the producer is fermentable. Since then many other groups have found 
paclitaxel-producing endophytes isolated from yew trees.41-44 Another advantage 
of endophytes was demonstrated in 2009 when a novel approach utilizing a 
fungal endophyte, Fusarium mairei, was co-cultured with Taxus cells resulting in 
the manufacture of 25.63 mg/L of paclitaxel within 15 days, a 38-fold increase 
from plant cells alone.45 For these reasons, endophytes are a potential goldmine 
for drug discovery from natural products.  
 
1.2.3. Mangroves as hosts for endophyte collection 
 
Mangroves live at the very interface of the marine and terrestrial world. They 
grow on shifting waterlogged ground, in water that rises and falls daily, and in 
some areas where the water transitions between salty and fresh. Mangroves 
filter, clean and recycle sediment, debris, organic materials and nutrients.46 
Endophytes living within mangroves must be able to survive the harsh conditions 
as well as wage a constant battle against competing bacteria and fungi in the 
microbe-plentiful seawater. 
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To the best of our knowledge Floridian mangroves have not yet been explored 
for compounds originating from endophytic organisms. The Floridian coastal 
ecosystem comprises three mangroves, the Red Mangrove 
(Rhizophora mangle), the Black Mangrove (Avicennia germinans) and the White 
Mangrove (Laguncularia racemosa) (Figure 1.4).47  
 
  
 
Figure 1.4. Images of mangroves native to Florida taken on the Everglades collecting trip:      
white (top left), black (top right) and red (bottom) mangroves.  
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The Southern temperature zone of Florida is considered subtropical and the 
Florida Keys environment is considered tropical. There are great differences in 
precipitation and plant hardiness zones in the State (Figure 1.5), creating a 
variety of microenvironments which further increases endophyte diversity. 
 
 
 
Figure 1.5. Florida Climate: annual precipitation (left) Copyright © 2006, PRISM Climate Group, 
Oregon State University, http://prism.oregonstate.edu Map created 2006 and plant hardiness 
zones (right) U.S. Department of Agriculture. 
 
Chemistry produced by endophytes of mangrove plants from around the world 
has been quite promising with anti-cancer and anti-infective bioactivity.48,49 Most 
recently, Ding and co-workers isolated the endophyte Streptomyces sp. HKI0576 
from the stem of a Bruguiera gymnorrhiza mangrove.  It was found to produce 
the divergolides, novel macrolides with antibiotic and cytotoxic properties. 
Divergolide A (1.25) and C (1.27) exhibited moderate activity against MRSA 
while divergolide D (1.28) displayed an IC50 of 1-2 µM activity against lung, 
pancreatic and renal cancer cells; where divergolide B (1.26) was inactive. 50 
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1.25: divergolide A                                                         1.26: divergolide B 
 
            
1.27: divergolide C                                                         1.28: divergolide D 
 
Pan and co-workers isolated the endophyte Sporothrix sp. from the bark of the 
Kandelia candel mangrove tree. This endophyte was found to produce three 
sporothrins. Sporothrins A (1.29) and B (1.30) were found to be modestly active 
against liver cancer cells with IC50 of 50 and 20 µg/mL, respectively, while 
sporothrin C was found to be inactive (1.31).51 
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1.29-1.30: sprothrin A  and B                                               1.31: sprothrin C 
 
 
Huang and co-workers isolated the endophyte Penicillium chermesinum also 
from the stem of a Kandelia candel mangrove tree. They found, amongst others, 
three p-terphenyls strongly bioactive against α-glucosidase with IC50 values of 
0.9, 4.9, and 2.5 µM, respectively.52 
 
 
 
1.32-1.34: terphenyls 4,5 and 6 
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1.3. Fungi and their refusal to perform in the laboratory 
1.3.1. Explanation of the problem 
 
Although the statistics favor continued efforts for drug discovery from natural 
sources, major pharmaceutical companies have cut back tremendously in recent 
years in part due to the frustrating obstacle of frequent rediscovery of 
compounds. Fungi in particular are difficult to work with in that they do not always 
produce the same variety and quantities of secondary metabolites under 
laboratory conditions.53 We are not yet able to replicate the organism’s natural 
environment and micro ecosystem artificially! As a result, metabolic pathways are 
silenced and an organism’s potential is never fully reached.54 To counteract this 
phenomenon, researchers have experimented with techniques to try to activate 
these ecological triggers unleashing new metabolic biosynthetic pathways. 
 
1.3.2. Solution 1: Variation of growth condition 
 
One of the early and most successful techniques has been to manipulate 
environmental factors such as the use of different media, growth conditions and 
forcing stressful growing conditions. For example, a study of 
Aspergillus ochraceus in 1994 revealed that aspinonene (1.35) was the only 
secondary metabolite present and at an average quantity of 8 mg/L.55 However, 
three years later the same group published another study after experimenting 
with different growth media, vessels and conditions for that same fungus, 
resulting in over a dozen other secondary metabolites (1.36-1.50) and in much 
greater quantities up to 94 mg/L.56  
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             1.35: aspinonene                         1.36: isoaspinonene                 1.37: aspyrone 
             
             1.38: dihydroaspyrone                        1.39: dientriol                     1.40: aspinolide A 
      
   1.41-1.42: aspinolides B, C                   1.43: triendiol                           1.44: xanthomegnin 
 
           1.45: asperloxin A                           1.46: asperloxin B                         1.47: asperloxin C 
 
       1.48: aspergamide A                     1.49: aspergamide B                     1.50: aspergamide C 
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This method has been time-tested to yield increased titers of natural products as 
well as potential new compounds. However it is very specific to each fungus and 
not translatable to a large collection. 
 
1.3.3. Solution 2: Co-culture 
 
Another idea established in the search to maximize fungal productivity is the 
simultaneous growth of the fungus of interest with a competing microorganism in 
the same fermentation. By allowing the fungus to grow in the presence of 
another, it will produce its secondary metabolites to defend itself. This method 
has been successful as shown in the example of the discovery of pestalone 
(1.51). The fungus Pestalotia sp. originally did not produce the potent antibiotic. 
However, after culturing the fungus in a mixed fermentation with an unidentified 
antibiotic-resistant marine bacterium, the novel benzophenone was obtained.57  
 
 
1.51: pestalone 
 
This inter-species association method has also been proven to produce new 
chemistry from fungi. However, it is also very specific to the fungus and the 
natural environment it is living in and not necessarily translatable across other 
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species. This obstacle renders the technique challenging for screening large 
numbers of endophytic fungi as well. 
 
1.3.4. Solution 3: Epigenetic modification 
 
An emerging topic in genetics, epigenetics, has recently earned a great deal of 
attention in both scientific and medical fields. The central dogma of molecular 
biology states that DNA provides the instructions to make RNA, and in turn RNA 
is translated by the ribosome to yield proteins that control cell activity. However, 
upon closer analysis, the process is highly regulated and exceedingly complex. 
Epigenetic studies provide the explanation for inherited changes in gene 
expression that are caused by mechanisms that are not encoded in DNA itself. 
These changes remain through cell divisions throughout generations. To achieve 
this control over gene expression the cell uses small molecules such as methyl 
or acetyl groups, to bind to DNA or histones, altering the genes expressed in 
response to an environmental stimulus. This explains an observed difference in 
metabolic profile when stress factors are introduced in the culture of fungi. As 
described in the previous section, when, for example, the fungus detects the 
presence of a hostile or competing organism in the environment, the fungus will 
activate certain genes that aid in combatting microbes or enduring the stressful 
circumstance. Figure 1.6 illustrates some of the mechanisms of action resulting 
in a different metabolic profile. Examining through to NIH’s genomic database, 
scientists have observed that fungi possess a greater quantity of gene encoded 
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for the production of secondary metabolites than the reported number of natural 
products isolated from those organisms.58 
 
 
Figure 1.6. Examples of posttranslational modifications. Model 1 illustrates a general structural 
change, while model 2 illustrates how a modification could inhibit binding due to the hindrance 
and finally model 3 illustrates how a modification could act as a binding site. Illustration adapted 
from Epigenetics Fig 1, p. 193 © Cold Spring Harbor Laboratory Press.61 
 
One of the most studied epigenetic inheritance systems is DNA methylation. 
Methylation involves the addition of a methyl group at the C-5 carbon of cytosine 
nucleotides. This process allows the cell to upregulate or downregulate genes.59 
Figure 1.7 depicts two models in which an activator protein is binding to an 
enhancer site in DNA. In the methylated model (top) it is unable to bind due to 
change in structure and hindrance from methyl groups near the enhancer site, 
thereby silencing the genes. A few recent studies have been successful 
activating silenced metabolic pathways by adding a methyltransferase inhibitor 
during the log phase of the fermentation, resulting in new compounds. For 
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example, a group was able to obtain six new azaphilones 1.52-1.57 and two 
meroterpenes 1.58-1.59 from modified culture conditions.60 
 
 
Figure 1.7. In the methylated model (top) the activator protein is unable to bind due to change in 
structure and hindrance from methyl groups near the enhancer site, thereby silencing the genes. 
When methylation is inhibited (bottom) the gene is activated. Illustration adapted from Genetics - 
Analysis and Principles Fig 15.14, p. 405 © McGraw-Hill. 
 
 
     1.52-1.53: sclerotiorin, sclerotioramine                                          1.54: ochrephilone                
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1.55-1.56: dechloroisochromophilone III, IV   1.57: 6-((3E,5E)-5,7-dimethyl-2-methylenenona-3,5-      
                                                                                 dienyl)-2,4-dihydroxy-3- methylbenzaldehyde 
 
                         1.58: atlantinone A                                                   1.59: atlantinone B                
 
Another way organisms regulate transcription is by modifying histones via 
acetylation or deacetylation. As illustrated in Figure 1.8, the histones are 
acetylated on lysine residues in the N-terminal tail creating an electronic effect 
that in turn gives chromatin a more relaxed structure. Initial studies concerning 
these processes state that the more relaxed the chromatin structure, the more it 
is left exposed to greater levels of transcription. In the reverse situation with 
deacetylation, DNA is more tightly bound around the histones and thus less likely 
to allow the transcription machinery to gain access.59 However, new evidence 
reveals that the process is not as simple as a binary code with general rules for 
positive or negative acting modifications. Several exceptions to have been 
observed.61 For example, a study using trichostatin A (1.60) in a culture of the 
fungus Neurospora crassa identified hypoacetylated histones leading to a 
substantial reduction in DNA methylation.62 Furthermore, early experiments using 
histone deacetylases or histone deacetylase inhibitors have been shown to 
activate silenced genes in both cases. 
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Figure 1.8. Histone acetylation.59 The histones are acetylated on lysine residues in the N-terminal 
tail creating an electronic effect that in turn gives chromatin a more relaxed structure. Illustration 
adapted from Genetics - Analysis and Principles Fig 12.15, p. 308 © McGraw-Hill. 
 
 
1.60: trichostatin A 
1.4. Research Objectives 
 
Mangrove fungal endophytes, though a relatively new niche in the natural 
products realm, have proven to yield important bioactive compounds. The work 
presented herein is a study of the isolation and characterization of anti-infective 
compounds from Floridian mangrove endophytes. Furthermore, epigenetic 
modifications were explored in order to increase the production of secondary 
metabolites as well as for the purpose of generating a new analog not found in 
controls. Finally, structure activity relationship studies were performed in order to 
explore the full potential of the active metabolite as well as gain an insight on 
pharmacophores of the molecule. 
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Chapter Two. Isolation of bioactive compounds from mangrove endophytes 
 
2.1. Field collection 
2.1.1. Sample selection and surface sterilization 
 
The Florida Department of Environmental Protection (DEP) enforces strict rules 
governing trimming and removal of mangroves as set by the Mangrove 
Protection Act. Furthermore, the entire region of the Florida Keys exists within 
wildlife preserve parks. Sample collection was discussed with Lucy Blair, a DEP 
agent in charge of environmental resource permitting, and three solutions were 
discussed. 
 
1) A permit can be obtained by applying for it 90-days prior to 
sample collection. 
2) Professional mangrove trimmers can be used as a resource 
in obtaining samples of mangroves since they are already 
permitted. 
3) Since the purpose of the collection trip is to obtain 
endophytic organisms and not actual pieces of mangroves, 
shavings or imprints from the tree can be obtained without 
the need for a permit (Figure 2.1). 
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Figure 2.1. Excerpt from email conversation with Florida DEP regarding the sampling. 
 
A specialized sampling kit was designed to surface sterilize mangrove pieces in 
place and then collect shavings of various parts of the mangroves in order to 
isolate the microorganisms. Since the target microbes are endophytes, the 
surface sterilization step is critical in obtaining only those living within plant cells. 
The mangrove parts to be sampled were surface sterilized in place (to comply 
with environmental regulations) by first immersing the section of the mangrove in 
70% isopropanol for 60 seconds, followed by a rinse of sterile water. Then, to 
insure that all environmental microbes or epiphytes are destroyed, the area is 
then immersed in a commercially available bleach solution (6.5% sodium 
hypochlorite) for 60 seconds, followed by a thorough rinse of sterile water. This 
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method was tested several times during development by making imprints of 
newly surface-sterilized portions on both bacterial and fungal favoring media and 
observing the growth over a two-week period. In all cases no organisms grew 
and the technique was deemed effective in eliminating surface microbes. Next, 
small pieces, not bigger than 4 cm2, were shaved from the mangrove’s root, bark, 
leaves, seeds and flowers. Four pieces of those shavings were arranged 
aseptically onto petri dishes containing varying media.  
 
When a permit was acquired and mangrove pieces could be removed, a different 
sampling technique was employed. This new method1 was preferable as it 
involved aseptic conditions. The techniques were learned during a 2-week 
training at the City University of Hong Kong under the supervision of Dr. Lilian 
Vrijmoed and involved the systematic sampling of mangrove branches and 
leaves in the laboratory rather than in the field. While the surface sterilization 
step remains the same as the previous method the cutting and removing of the 
samples was changed. As illustrated in Figure 2.2, there are 5 main components 
sampled from each branch. Section A branch thickness is 13–17 mm, B is 7–
11 mm, C is 3–7 mm and D is 2.5–4 mm. A 20 mm segment of each section is 
cut and then four pieces of bark are removed from the xylem and aseptically 
placed on petri dishes containing varying media. Leaves are treated differently. 
First the vein is cut out of the leaf and then sectioned into 2 mm pieces. Four of 
those pieces are then arranged aseptically onto petri dishes containing varying 
media. 
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Figure 2.2. Diagram illustrating the collection scheme for mangrove branch samples. Section A 
branch thickness is 13–17 mm, B is 7–11 mm, C is 3–7 mm and D is 2.5–4 mm. 1  
 
2.1.2. Selective media: choices, additives and specialization 
 
Cultivation efforts typically utilized five to six different types of media in order to 
maximize biodiversity (Figure 2.3). The basic media used in preparing the field 
kits were Sabouraud dextrose (SDA), a low pH medium that favors fungi; malt 
extract (MEA), a very rich medium with high pH; potato dextrose (PDA), the most 
commonly used fungal medium; and cornmeal, a medium formulated for the 
growth of phytopathological fungi. To increase the likelihood of greater diversity, 
at least three of these were selected for each trip and prepared in different ways. 
The first was typically prepared according to the manufacturer’s directions. The 
second was mixed with autoclaved seawater (or an artificial aquarium salt 
additive) instead of fresh water, which discourages microorganisms that cannot 
tolerate 3.5% salt in the media. The third was prepared according to directions, 
but just before it was poured into petri dishes (and the temperature fell to about 
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50 °C), the antibiotic chloramphenicol (2.1) was added at a concentration of 
0.2 g/L. Chloramphenicol was chosen because it has a very broad spectrum of 
activity, inhibiting Gram-positive, Gram-negative bacteria,2 thus allowing fungi to 
develop without the presence of bacteria resulting in a greater variety in 
endophytes. 
 
2.1. chloramphenicol 
 
In addition, specialty medias were prepared for the field kit. One, the mangrove 
sawdust media, was developed to try to mimic the natural environment of 
endophytes as well as favor cellulose-digesting fungi. This medium was prepared 
by taking mangrove branches and leaves and placing them in a laboratory 
blender with deionized water. The mixture was homogenized and then 
lyophilized. The resulting sawdust was mixed into deionized water in the quantity 
of 10 g/L with 15 g/L of agar. Another very restrictive medium that was explored 
was Melin-Norkrans, which favors slower-growing fungi. Finally, bacteria-favoring 
media were used: Difco Marine mimics the nutrient conditions in seawater and 
Actinomyces media made with glycerol allows actinomyces bacteria to grow 
while discouraging others. 
 
HN
O
Cl
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N+
O
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OH OH
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Figure 2.3. Media selection overview 
 
2.1.3. Isolation and storage of endophytic microbes 
 
Cultures were allowed to develop for 2-3 days undisturbed at ambient laboratory 
conditions and then observed every day for 4 weeks from collection. Any fungi 
that grew were isolated as early as possible by aseptically cutting a single strand 
of mycelium and placing it onto a fresh petri dish with a universal fungal media 
such as SDA. Bacterial endophytes were isolated by selecting a single colony 
with an inoculating loop and transferring to a fresh petri dish of Trypticase soy 
agar (TSA). The basis of selection reflected variations in morphology, spores (if 
applicable), color, and time of development. Isolated strains were observed after 
5 days of growth and, if pure, archived. If impure, then the microorganism was re-
isolated on fresh petri dishes repeatedly until deemed pure by visual inspection 
or by microscopy. Each isolate was given a unique identifying code to keep track 
of its origin, year, host and media preference. The code (ie: KL08-17B-2) was as 
follows: two letters for the location (KL = Key Largo), the last two digits of the 
collection year (ie: 08 = 2008) then a two digit number for sample host (17 = red 
Sabouraud Dextrose
Potato Dextrose
Malt Extract
Cornmeal
Regular
Seawater
Chloramphenicol
Media Selection Specialty Media
Mangrove Sawdust
Melin-Norkrans Medium
Actinomyces Medium
Difco Marine
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mangrove flower, in that collection), a letter representing the media (B = SDA) 
and then the last sequential numbers represent the isolate (2 = second microbe 
isolated from that original petri dish). Fungal isolates were archived in two ways: 
first a plug of agar supporting mycelium growth was placed into a slant tube with 
SDA and stored in the laboratory at ambient conditions; second 5-6 plugs of agar 
supporting mycelium growth were placed into a cryotube with 1 mL of a 20% 
glycerol solution and stored at -80°C. Bacterial isolates were cultured in 
Trypticase soy broth (TSB) for 48h at ambient temperatures and then mixed in 
equal parts with 20% glycerol and stored at -80°C. 
 
2.1.4. Growth, extraction and preparation of crude extracts 
 
Fungi were inoculated onto two petri dishes containing SDA by aseptically 
transferring three pieces of mycelium onto each. These cultures were allowed to 
develop and mature for at least 18 days, but typically 21 days at ambient 
laboratory conditions. Bacteria were inoculated into 100 mL tubes containing 
30 mL of TSB and shaken on a rotary shaker for 10 days at ambient laboratory 
conditions. After the incubation period cultures were lyophilized until completely 
dry. Following freeze-drying, the residues of each culture were extracted three 
times with methanol to produce a crude extract. These extracts were placed in 
96 well plates and sent to our collaborator for malaria screening as well as tested 
in the laboratory using disk diffusion antibiotic susceptibility assay against MRSA. 
 
	   38	  
2.1.5. Collection sites, results and statistics 
 
Seven trips (Table 2.1) were planned and executed in many areas around the 
State of Florida. The first was carried out in the fall of 2007 in the area of Jewfish 
Creek in Key Largo, FL. This collection was crucial in establishing the surface 
sterilization techniques as well as learning to process samples from a canoe. 
This collection, KL07, resulted in the isolation of 46 microorganisms. The next trip 
was in the spring of 2008 near John Pennekamp Park in Key Largo. This 
collection, KL08 resulted in the isolation of 156 endophytes. A small collection 
was done at the Keys Marine Laboratory in Long Key in the fall of 2008. This trip, 
LK08 resulted in the isolation of 41 microorganisms. Another trip was done at 
one of the major bridges between Clearwater and Tampa, the Courtney 
Campbell Causeway. This collection, CC08, resulted in the isolation of 106 
endophytes. In the summer of 2009, the training in Hong Kong took place to be 
able to isolate greater numbers and more diversity. Subsequently, in the fall of 
2009 a major trip was planned and executed in the Florida Everglades. This 
collection, EG09, resulted in the isolation of 293 endophytes. In the spring of 
2010, another Courtney Campbell trip was done. This trip, CC10, resulted in the 
isolation of 204 microorganisms. Finally, the last trip planned was in the summer 
of 2010 in the Florida Everglades. This was the most successful trip, EG10, with 
661 organisms isolated.   
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Table 2.1. Summary of collecting trips around Florida 
Code Year Location Isolates 
KL07 2007 Jewfish Creek, Key Largo 46 
KL08 2008 John Pennekamp Park, Key Largo 156 
LK08 2008 Keys Marine Laboratory, Long Key 41 
CC08 2008 Courtney Campbell Causeway, Tampa 106 
EG09 2009 Florida Everglades, Everglades City 293 
CC10 2010 Courtney Campbell Causeway, Tampa 204 
EG10 2010 Florida Everglades, Everglades City 661 
Total 1507 
 
Most of the collection was tested against malaria and MRSA. However, the most 
relevant statistics originate from the last two collections CC10 and EG10. Out of 
528 fungal extracts tested, 19 were found to be active against MRSA, a 3.6% hit 
rate. Against malaria there were 4 active (>67% inhibition at both 50 µg/mL and 
5 µg/mL) and 9 partially active (33% to 67% inhibition at 50 µg/mL and >33% 
inhibition or no inhibition at 5 µg/mL), a total hit rate of 2.5%. The following 
section details the separation, isolation and structure elucidation of some of the 
active extracts. 
 
2.2. Bioassay-guided isolation of anti-infective compounds 
2.2.1. Macrolactin A 
 
Isolate KL-08-05A-3 was a cream colored bacterium isolated from the bark of a 
red mangrove root. A sequence of the 16s rRNA resulted in a 99% match to 
Bacillus sp. against the BLAST database. Having shown a 28 mm zone of 
inhibition (ZOI) against MRSA at the crude extract level, the isolation was 
bioassay guided against the bacterium. The extract (8.2 g) was fractionated 
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using medium pressure liquid chromatography (MPLC) and the active fraction 
was purified via high pressure liquid chromatography (HPLC) yielding 26.1 mg of 
yellow oil active against MRSA recorded as JFB1. It was found to have the 
molecular formula of C24H34O5 by HRESIMS m/z 425.2297 [M+Na]+ (calculated 
for C24H34O5Na, 425.2310). Structure elucidation was accomplished via 
interpretation of 1D and 2D NMR spectroscopy (1H, 13C, gCOSY, gHSQC, 
gHMBC). 
 
 
Figure 2.4. Isolation scheme for macrolactin A from a strain of Bacillus sp. 
A                B                C               D                E                F                G               H                I
1                  2                  3                 4                   5                    6                  7
KL08-05A-3 (8.2 g)
Silica MPLC – Hexane – EtOAc – MeOH
C18 HPLC – Water – MeOH
JFB1 - Macrolactin A
26.1 mg
1 mg        45 mg       105 mg       216 mg      304 mg      112 mg       401 mg     1022 mg       6.3 g
12.6 mg       29.2 mg        0.4 mg        8.9 mg        43.1 mg          20.1 mg        9.8 mg
Silica HPLC - 80% EtOAc
	   41	  
Starting from the doublet methyl signal at δ 1.28 (3H, H-24) and using COSY 
correlations it was evident that the neighboring proton was a methine at δ 5.03. 
This C-23 carbon was identified using HSQC correlations and the chemical shift 
of 71.0 ppm indicated that it was oxygen bearing. The HMBC spectrum showed 
that the H-23 methine correlated with the carbon at δ 166.4, indicating an ester 
on one side, as well as carbons at δ 34.9, δ 24.4 and δ 19.9, indicating an 
aliphatic moiety and on the other side an ester. Continuing with HMBC, C-1 had 
correlations with that proton at δ 6.16 and δ 5.60. Those proton shifts are 
characteristic of olefins, with the one further downfield being a conjugated olefin. 
Using this information, H-2 was assigned at 5.60 ppm and H-3 at 6.16 ppm. From 
there, the structure was solved using COSY correlations (Figure 2.5) as the rest 
of the molecule consisted of contiguous protonated carbons. H-3 correlated with 
the proton at δ 7.19 (H-4), which in turn correlated with the proton at δ 5.78 (H-5). 
The H-5 shift indicated the end of the conjugation for this portion of the molecule 
and correlated to two protons (H-6) at δ 2.47 and δ 2.41. One of them (2.47 ppm) 
correlated with δ 4.35 (H-7). The chemical shift of the C-7 carbon (71.1 ppm) 
indicated the presence of a C-O bond.  
 
 
Figure 2.5. Partial structure for JFB1 indicating key COSY (blue) and HMBC (red arrows) 
correlations. 
 
O
O
OHOHOH
                                      15              13                                                     7                                                      1                23
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H-7 correlated to δ 5.57 (H-8), then that proton to δ 6.59 (H-9), and that proton to 
δ 6.02 (H-10). H-10 correlated to δ 5.50 showing again a pair of conjugated 
olefins between C-8 to C-11. H-11 correlated to the methylene (C-12) with 
protons at δ 2.54 and δ 2.51, both of which in turn correlated to the proton δ 3.98 
(H-13). This C-13 carbon had a chemical shift of 69.5 ppm, indicating the 
presence of a C-O bond. Continuing, H-13 correlated to another methylene (C-
14) with protons at δ 1.73 and δ 1.65. This former correlated to the proton at 
δ 4.51 (H-15), another oxygen-bearing carbon (C-15, 70.0 ppm). Continuing, H-
15 correlated with the proton at δ 5.60 (H-16), which then correlated with proton 
at δ 6.55 (H-17); that proton with δ 6.10 (H-18) and in turn that proton with δ 5.58 
(H-19); again a conjugated two-olefin system. H-19 correlated with the methylene 
(C-20) with protons at δ 2.17 and δ 2.10 (H-20). From this point COSY became 
difficult to use because of the ambiguity of the multiplets of both H-21 and H-22 
at δ 1.50. The molecular formula of C24H34O5 has a degree of saturation of 8. 
With 7 already identified and neither olefins nor carbonyls left on the proton and 
carbon spectrum the only possibility is a monocyclic system. Using the HMBC 
information for H-23 described above, there are two unassigned methylenes left. 
Looking from the other side of the molecule, H-20 correlated to δ 34.9 and δ 24.4 
as well (Figure 2.6). 
 
Figure 2.6. Partial structure for JFB1 indicating key COSY (blue) and HMBC (red arrows) 
correlations for the closing of the ring system. 
 
O 23               21             19
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Thus the ring system comprises the entire molecule linked by these two carbons. 
Since H-23 showed COSY correlations to both δ 1.57 and δ 1.50 as well as the 
occurrence of splitting, it was determined that those were connected to C-22 and 
that the other two at δ 1.50 belonged to C-21. With only 3 protons left in the 
molecule, it was resolved that oxygen at C-7, C-13 and C-15 were hydroxyl 
groups. With the planar structure solved, a comprehensive literature search was 
done and the molecule was found to be similar to the class of macrolactins. A 
comparison of proton and carbon shifts (Table 2.2) confirmed the identity of JFB1 
to be macrolactin A (2.2). Macrolactin A was isolated by the Fenical group in 
1989 from an unknown marine bacterium and was found to be antiviral and 
cytotoxic3 as well as broadly antibiotic against Gram-positive bacteria, including 
MRSA.4 
 
In our bioassays, macrolactin A had an MIC of 18 µM against MRSA-1 
(ATCC 33592), was inactive against MRSA-2 (USA 300, a community acquired 
strain) and as well as inactive against MRSA-3 (USA 100, a hospital acquired 
ultra-resistant strain). In addition it was tested against malaria (W2 strain of 
P. falciparum) and had an IC50 of 17 µM. Finally, it was tested in our cytotoxicity 
assay (A549 cells) and had an IC50 of 25 µM. 
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Table 2.2. Comparison of JFB1 with macrolactin A 
 
JFB1 macrolactin A (2.2)3 
Position δHa δCb δHc δCd 
1 
 
166.4 
 
166.3 
2 5.60 (d) 117.9 5.68 (d) 117.8 
3 6.17 (dd) 142.8 6.29 (dd) 143.7 
4 7.19 (dd) 129.6 7.48 (dd) 129.4 
5 5.78 (dd) 139.8 5.85 (ddd) 142.4 
6 2.41 (m) 40.7 2.30 (m) 42.8 
 
2.47 (m) 
 
2.35 (m) 
 7 4.35 (q) 71.1 4.15 (m) 71.2 
8 5.57 (dd) 136.1 5.58 (dd) 138.3 
9 6.59 (dd) 124.6 6.73 (dd) 124.9 
10 6.02 (dt) 130.2 6.04 dd) 130.6 
11 5.50 (m) 127.4 5.42 (m) 128.6 
12 2.51 (m) 
 
2.43 (m) 
 
 
2.54 (dt) 35.3 2.70 (m) 36.7 
13 3.98 (m) 69.5 4.03 (m) 68.8 
14 1.65 (dt) 41.6 1.74 (m) 43.9 
 
1.73 (ddd) 
 
1.83 (m) 
 15 4.51 (q) 70.0 4.62 (m) 69.2 
16 5.60 (t) 134.8 5.70 136.6 
17 6.55 (dd) 130.5 6.35 (dd) 131.2 
18 6.10 (dd) 130.1 6.08 (dd) 129.6 
19 5.58 (d) 133.0 5.70 133.7 
20 2.10 (dq) 32.0 1.91 (m) 32.3 
 
2.17 (dq) 
 
2.06 (m) 
 21 1.50 (2H, td) 24.4 1.32 (2 H, m) 25.0 
22 1.50 (m) 34.9 1.32 (m) 35.3 
 
1.57 (m) 
 
1.49 (m) 
 23 5.03 (m) 71.0 5.10 (m) 70.8 
24 1.28 (3H, d) 19.9 1.09 (3 H, d) 19.9 
aRecorded at 500 MHz in CDCl3, bRecorded at 125 MHz in CDCl3, cRecorded 
at 360 MHz in C6D6, dRecorded at 50 MHz in pyridine-d5 
 
	   45	  
 
2.2. macrolactin A 
 
2.2.2. Sch 54796 
 
Isolate KL-08-17A-2 was a brown fungus isolated from a red mangrove flower. 
Having shown >33% inhibition at 50 µg/mL and >33% inhibition 5 µg/mL against 
malaria at the crude extract level, the isolation was bioassay guided against 
parasites. The extract (1.2 g) was fractionated using MPLC and the active 
fraction was purified via HPLC yielding 2.1 mg of white powder moderately active 
against malaria. JFB2 was found to have a molecular formula of C18H24N2O3 by 
HRESIMS m/z 403.1129 [M+Na]+ (calculated for C18H24N2O3Na, 403.1126). 
Structure elucidation was accomplished via interpretation of 1D and 2D NMR 
spectroscopy (1H, 13C, gCOSY, gHSQC, gHMBC). 
 
O
OH
O
HO
HO CH3
	   46	  
 
Figure 2.7. Isolation scheme for Sch 54796 from an unidentified fungus 
 
The two singlet methyl signals at δ 1.71 (H-16) and δ 1.67 (H-15) had the same 
HMBC correlations as each other with olefinic carbons at δ 136.8 and δ 120.1. 
This indicated the possibility of an isoprene unit in the molecule. The HSQC 
spectrum showed the lack of proton correlation at the 136.8 ppm carbon, thus 
assigning it as C-14 and the other at 120.1 ppm as C-13. A COSY correlation 
was present from H-13 (δ 5.37) to δ 4.45 (2H, H-12) an oxygen-bearing 
methylene (C-12, 64.2 ppm). From there, the HMBC spectrum showed a 
correlation past the oxygen to the carbon δ 157.6 (C-11). This carbon had the 
additional correlations to the two doublets signals in the conjugated olefin region 
A                B                C               D                E                F
1                  2                  3                 4                   5                    6                  7                   8                   9                 10
KL08-17A-3 (1.2 g)
Silica MPLC – Hexane – EtOAc – MeOH
C18 HPLC – Water – MeOH
JFB2 - Sch 54796
2.1 mg
4 mg          12 mg        18 mg        84 mg         43 mg       917 mg
0.1 mg        1.1 mg          2.0 mg       1.8 mg          0.5 mg           2.3 mg         1.4 mg          2.2 mg         0.4 mg          3.2 mg
Silica HPLC - 25% EtOAc
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of the proton spectrum, δ 7.16 (2H) and δ 6.81 (2H). The two signals are typical 
of a para-substituted benzene ring. While the 6.81 ppm proton had correlations 
with carbons at δ 131.9 and δ127.0, the 7.16 ppm proton also had two 
correlations, with carbons at δ 127.0 and δ 114.2 but also one additional one to 
the carbon outside the ring at δ 41.3 (C-7). This allowed for the assignment of H-
10 for the former and H-9 for the ladder while the common correlation between 
the two at carbon δ 127.0 was assigned as C-8. From the methylene protons at 
H-7 (δ 3.41 and δ 2.82), there were correlations to carbons at δ 164.9 and 
δ 68.2. The former carbon is indicative of an ester or amid while the latter was 
high for an aliphatic carbon and low for an oxygen-bearing carbon, suggesting 
the possibility of a sulfur-bearing carbon. 
 
Figure 2.8. Structure for JFB2 indicating key COSY (blue bond) and HMBC (red arrows) 
correlations 
 
 
HN
NH
O
O
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O
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Correlations from this carbon were to the proton at δ 8.55, possibly an N-H, and 
the methyl singlet at δ 2.14. These correlations shed light on the previous 
assumptions that there was the presence of an amid as well as an S-methyl. This 
led to the assignment of the 68.2 ppm carbon as C-6, the carbonyl carbon as C-5 
and the downfield proton (N-H) as H-4. This proton had more correlations, to 
carbons δ 57.4 (C-3), another S-methyl and δ 163.9 (C-2), another amid 
carbonyl. The C-2 carbon exhibited a correlation to the N-H proton at δ 9.03     
(H-1). Finally, this H-1 proton showed a correlation to C-6, thus closing the 
diketopiperazine ring. With the planar structure solved, a comprehensive 
literature search was done and the molecule was similar to a certain class of 
diketopiperazines. A comparison of proton and carbon shifts (Table 2.3) 
confirmed the identity of JFB2 to be Sch 54796 (2.3). 
 
 
In our bioassays, Sch 54796 and had an IC50 of 60 µM against malaria. In 
addition it was tested against MRSA but was found to be inactive against all 
three strains. Finally, it was tested in our cytotoxicity assay and was found to be 
moderately cytotoxic, with an IC50 < 60 µM . To the best of our knowledge, this 
compound has been previously described, but no malarial data was known. 
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Table 2.3. Comparison of JFB2 with Sch 54796 
 JFB2 Sch 54796 (2.3)
5 
Position δHa δCb δHc δCc 
1 9.03 (s) 
 
  
2 
 
163.9  165.5 
3 5.05 (d) 57.4 4.93 (s) 57.8 
4 8.55 (s) 
 
 
 5 
 
164.4  165.9 
6 
 
67.7  68.0 
7 3.41 (d) 41.3 3.60 (d) 42.4 
 
2.82 (d) 
 
2.95 (d) 
 8 
 
127.0  126.1 
9 7.16 (d) 131.9 7.19 (d) 132.0 
9' 7.16 (d) 131.9 7.19 (d) 132.0 
10 6.81 (d) 114.2 6.83 (d) 114.6 
10' 6.81 (d) 114.2 6.83 (d) 114.6 
11 
 
157.6  158.5 
12 4.45 (2H, d) 64.2 4.47 (d) 64.5 
13 5.37 (t) 120.1 5.46 (t) 119.4 
14 
 
136.8  138.3 
15 1.67 (3H, s) 25.4 1.74 (s) 25.1 
16 1.71 (3H, s) 18.0 1.79 (s) 17.4 
17 2.14 (3H, s) 9.1 2.22 (s) 9.7 
18 1.14 (3H, s) 12.7 1.48 (s) 12.2 
aRecorded at 500 MHz in CDCl3, bRecorded at 125 MHz in CDCl3, 
bRecorded in CDCl3 and MeOD. 
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2.2.3. Chaetomin 
 
Isolate EG09-01B-1 was a white fungus with a light pink center isolated from the 
bark of a red mangrove aerial root. Having shown a 22 mm ZOI against MRSA at 
the crude extract level, the isolation was bioassay guided against the bacterium. 
The extract (7.6 g) was fractionated twice in alternating solid phases via MPLC 
and the active fraction was purified using HPLC yielding 1.1 mg of white powder 
active against MRSA. JFB3 was found to have the molecular formula of 
C31H30N6O6S4 by HRESIMS m/z 733.1024 [M+Na]+ (calculated for 
C31H30N6O6S4Na, 733.1007). With the new resource, the Antimarine database,6 
the structure was dereplicated using the high resolution mass data and found to 
potentially be the compound chaetomin (2.4). Originally isolated as a substance 
with an unknown structure in 1944, chaetomin was found to be broadly antibiotic 
against Gram-positive bacteria.7 A comparison of the proton and carbon NMR 
shifts (Table 2.4) with a later study of the compound in which Brewer elucidated 
the structure confirmed the identity of the molecule.8 
 
2.4. chaetomin 
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N
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Figure 2.9. Isolation scheme for chaetomin from an unidentified fungus 
 
 
In our bioassays, chaetomin had an MIC of 4 µM, 42 µM and 7 µM against 
MRSA-1, MRSA-2 and MRSA-3 respectively. In addition it was tested against 
malaria and had an IC50 of 77 µM. Finally, it was tested in our cytotoxicity assay 
and had an IC50 of 7 µM. 
 
A                B                C               D                E                F
1                  2                  3                 4                    5                   6                  7                   8
EG09-01B-1 (7.6 g)
Silica MPLC – Hexane – EtOAc – MeOH
C18 MPLC – Water – MeOH
JFB3 - Chaetomin
1.1 mg
54 mg        253 mg       74 mg        101 mg       942 mg        5.4 g
3.1 mg        163 mg         42.0 mg      9.8 mg          12.5 mg          4.3 mg        0.4 mg          2.2 mg
Silica HPLC - 85% EtOAc
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Table 2.4. Comparison of JFB3 with chaetomin 
 
JFB3 Chaetomin (2.4)8 
Position δHa δCb δHc δCd 
1 
 
165.5 
 
165.5 
2 
    3 
 
76.1 
 
76.3 
4 
 
163.3 
 
163.1 
4a 
    5 6.21 (s) 80.1 6.17 80.2 
6 5.32 (s) 
 
5.44 
 6a 
 
148.4 
 
148.4 
7 6.80 (d) 111.2 6.75 111.1 
8 7.23 (t) 125.1 7.23 125.0 
9 6.95 (t) 120.4 6.9 120.3 
10 7.23 (t) 131.5 7.22 131.4 
10a 
 
126.6 
 
126.7 
10b 
 
73.8 
 
73.8 
11 4.42 (d) 42.7 4.49 42.7 
 
3.09 (d) 
 
3.09 
 11a 
 
73.6 
 
73.6 
12 4.35 (2H, m) 60.7 4.72 60.4 
13 2.96 (s) 27.5 2.93 27.5 
1' 
 
165.6 
 
165.6 
2' 
    3' 
 
76.6 
 
76.6 
4' 
 
166.9 
 
166.8 
5' 
    6' 
 
74.8 
 
74.9 
7' 2.61 (s) 27.1 2.62 27.1 
8' 
 
107.7 
 
107.8 
9' 7.34 (d) 127.3 7.34 127.3 
10' 
    10a' 
 
134.1 
 
134.1 
11' 7.30 (t) 111.4 7.29 111.5 
12' 7.19 (s) 122.9 7.19 122.8 
13' 7.19 (s) 120.6 7.19 120.6 
14' 7.67 (d) 119.2 7.64 119.2 
14a' 
 
130.4 
 
130.4 
15' 4.01 (2H, m) 61.3 4.72 61.1 
16' 3.17 (3H, s) 27.4 3.14 27.5 
17' 3.20 (3H, s) 28.3 3.15 28.3 
aRecorded at 500 MHz in CDCl3, bRecorded at 125 MHz in CDCl3, 
cRecorded at 100 MHz in CDCl3, dRecorded at 25 MHz in CDCl3 
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2.2.4. Beauvericin and bostrycoidin-9-methyl ether 
 
Isolate EG09-15B-2 was a pink fungus isolated from the bark of Coccoloba 
uvifera, commonly known as the Seagrape (Figure 2.10). This plant was in the 
same location as mangroves in the collecting trip and was also sampled.  
 
 
Figure 2.10. Coccoloba uvifera, commonly known as the Seagrape. Forest & Kim Starr 
http://www.hear.org/starr/plants/images/image/?q=080604-6302. 
 
Having shown >75% inhibition at 50 µg/mL and >50% inhibition 5 µg/mL against 
malaria at the crude extract level, the isolation was bioassay guided against the 
parasites. The extract (2.3 g) was fractionated with C-18 MPLC and two active 
fractions were present. Those fractions greatly varied in color (one red and the 
other colorless) and thus were separated further individually using silica MPLC. 
Each had one active peak that was purified using HPLC yielding 206.2 mg of 
white waxy powder for JFB4 and 5.6 mg of red needle-like crystals for JFB5, both 
of which were active against malaria.  
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Figure 2.11. Isolation scheme for the isolation of beauvericin and bostrycoidin-9-methyl ether 
from an unidentified fungus 
 
JFB4 was identified as the peptide beauvericin (2.5) using low resolution mass 
data (m/z 784.4 [M+H]+) along with proton and carbon NMR spectroscopy as 
compared to the Antibase database. The NMR shifts were compared against the 
literature and found to be identical (Table 2.5).9 Beauvericin was isolated in 1969 
and was found to be mildly antibiotic.10 However, in 1980 it was found to be 
greatly insecticidal11 and recently, the beauvericin-producing, entomopathogenic 
fungus Beauveria bassiana has been used in mosquito control in the fight against 
malaria.12 
 
A                B                C               D                E                F
EG09-15B-2 (2.3 g)
C18 MPLC – Water - Methanol
C18 HPLC – 45% ACN
JFB5 - Bostrycoidin-9-methyl ether
5.6 mg
1692 mg       71 mg          2 mg         80 mg        174 mg       40 mg
JFB4 - Beauvericin
206.2 mg
1                 2                 3                 4                 5                 6
51.7 mg      28.4 mg      24.9 mg      269.8 mg     28 mg       24.5 mg
1                 2                 3                 4                 5                 6                 7                  8                 9
6.6 mg        3.2 mg        26.8 mg       5.1 mg        1.3 mg        25.7 mg      5.7 mg         3.1 mg       1.6 mg
C18 HPLC – 55% ACN
Silica MPLC - Hexane - EtOAC
Silica MPLC - Hexane - EtOAc - Methanol
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2.5. beauvericin 
 
Table 2.5. Comparison of JFB4 with beauvericin 
  JFB4 Beauvericin9 
Position 1Ha 13Cb 1Hc 13Cd 
1  170.0  169.93 
2-N 
  
 
 3 4.81 (d) 56.8 4.93 (d) 56.46 
4  169.9  169.22 
5-O 
  
 
 6 5.62 (d) 75.7 5.42 (dd) 75.40 
7 3.02 (3H, s) 34.7 2.98 (3H, s) 34.76 
8 2.93 (dd) 31.9 2.96 (m) 32.47 
 3.39 (dd) 
 
3.34 (dd) 
 9 
 
136.4  136.70 
10 7.26-7.14 (m) 128.5 7.23 (m) 128.53 
11 7.26-7.14 (m) 128.7 7.23 (m) 128.92 
12 7.26-7.14 (m) 126.8 7.23 (m) 126.75 
13 1.93 (dq) 29.7 2.03 (m) 29.69 
14 0.78 (3H, d) 18.4 0.79 (3H, d) 18.31 
15 0.35 (3H, d) 17.1 0.42 (3H, d) 17.55 
aRecorded at 500 MHz in CDCl3, bRecorded at 125 MHz in CDCl3, 
cRecorded at 400 MHz in CDCl3, dRecorded at 100 MHz in CDCl3 
  
  
N
O
N O
O
N
O
O
O
O
O
O
1
3
6
7
9
11
14
15
	   56	  
In our bioassays, beauvericin had an IC50 of 4 µM against malaria. In addition it 
was tested for anti-MRSA activity and had an MIC of 38 µM versus MRSA-1 but 
was found to be inactive against the other two strains. Finally, it was tested in our 
cytotoxicity assay and found to have an IC50 of 14 µM. To the best of our 
knowledge, this compound has been previously described, but no malarial data 
was known. 
 
For JFB5, the structure was elucidated by X-ray crystallography (Figure 2.12) 
since crystals were obtained from the pure compound. Though this compound 
was not present in the crystal structural database, a literature search revealed 
that the compound was bostrycoidin-9-methyl ether (2.6).  
 
 
Figure 2.12. The molecular structure of bostrycoidin-9-methyl ether (2.6) as determined by SXRD 
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2.6. bostrycoidin-9-methyl ether 
 
Bostrycoidin-9-methyl ether, also known as 8-O-methylbostrycoidin ether, was 
originally isolated from a fungus in 1980 and shown to have some antibiotic 
properties.13 In our bioassays, bostrycoidin-9-methyl ether had an IC50 of 3 µM 
against malaria. It was not tested against MRSA due to lack of material. Finally, it 
was tested in our cytotoxicity assay and found to have an IC50 greater than 
334 µM (the upper limit for the assay is 100 µg/mL). This compound has been 
previously described, but no malarial data was known, to the best of our 
knowledge. 
 
2.2.5. Roquefortine C 
 
Isolate EG09-10B-4 was a green powdery mold fungus isolated from the bark of 
a black mangrove trunk. It was identified via microscopy. Compared to the 
Barnett and Hunter identification guide,14 it was found to be Penicillium sp. 
Having shown a 16mm ZOI against MRSA at the crude extract level, the isolation 
was bioassay guided against the bacteria. The extract (2.3 g) was fractionated 
twice in alternating solid phases via MPLC and the active fraction was purified 
using HPLC yielding 1.4 mg of white powder active against MRSA. 
N
O
OH O
OO
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Figure 2.13. Isolation scheme for roquefortine C from Penicillium sp. fungus 
 
JFB6 was found to have the molecular formula of C22H23N5O2 by HRESIMS 
m/z 390.1937 [M+H]+ (calculated for C22H24N5O2, 390.1930). The structure was 
dereplicated using the molecular formula along with the proton and carbon 
spectral data and found to potentially be the compound roquefortine C (2.7). 
Originally isolated by Ohmomo in 1975,15 roquefortine C was found to be 
antibiotic against many Gram-positive bacteria.16 A comparison of the proton and 
carbon NMR shifts (Table 2.6) confirmed the identity of the molecule.17 
A                B                C               D                E                F               G                H                I
1                  2                  3                 4                   5                    6                  7
EG09-10B-4 (2.3 g)
C18 MPLC – Water – MeOH
JFB6 - Roquefortine C
1.4 mg
1.9 g          49 mg        14 mg         9 mg          18 mg         5 mg          2 mg          5 mg          29 mg
2.6 mg          1.2 mg         1.0 mg        1.9 mg          2.2 mg          4.6 mg          1.7 mg
C18 HPLC - 20% ACN
Silica MPLC – Hexane – EtOAc - MeOH
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2.7. roquefortine C 
Table 2.6. Comparison of JFB6 with roquefortine C 
JFB6 roquefortine C17 
1Ha 13Cb 1Hc 13Cd 
13.01 (br, s) 166.4  167.0 
8.53 (br, s) 159.4 8.87 (br, s) 159.4 
7.72 (br, s) 149.9 7.70 (br, s) 149.9 
7.28 (s) 143.3 7.28 (s) 143.3 
7.18 (d) 136.9 7.19 (d) 136.8 
7.11 (t) 135.2 7.11 (t) 135.1 
6.78 (t) 129.1 6.78 (t) 129.1 
6.61 (d) 128.5 6.61 (d) 128.5 
6.28 (s) 125.2 6.33 (s) 125.1 
5.99 (dd) 121.4 5.99 (dd) 121.6 
5.64 (s) 119.2 5.65 (s) 119.1 
5.15 (d) 114.8 5.16 (d) 114.8 
5.12 (d) 110.6 5.12 (d) 111.3 
4.98 (s) 109.2 4.99 (s) 109.1 
4.06 (dd) 78.5 4.07 (dd) 78.4 
2.60 (dd) 69.9 2.61 (dd) 70.5 
2.48 (t) 61.5 2.48 (dd) 61.5 
1.15 (3 H, s) 58.8 1.16 (3 H, s) 58.8 
1.04 (3 H, s) 40.9 1.04 (3 H, s) 40.9 
 
36.7 
 
36.8 
 
22.9 
 
22.9 
 
22.5 
 
22.5 
aRecorded at 500 MHz in CDCl3, bRecorded at 125 MHz in 
CDCl3, cRecorded at 360 MHz in CDCl3, dRecorded at 90 MHz 
in CDCl3 
 
In our bioassays, roquefortine C had an MIC of 129 µM, 257 µM and 26 µM 
against MRSA-1, MRSA-2 and MRSA-3, respectively. It was inactive against 
malaria and had IC50 greater than 357 µM in the cytotoxicity assay. 
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2.3. Summary and conclusion 
 
In conclusion, six structurally-varied known compounds have successfully been 
isolated and identified from mangrove endophytes. Their anti-infective activity 
was tested against the W2 strain of the P. falciparum malaria-causing parasites 
as well as several strains of MRSA. In addition they were tested for cytotoxicity 
against human cells. 
 
Table 2.7. Summary of biological activity of compounds isolated from mangrove endophytes. 
Structure 
 
 
 
Molecule Code JFB1 (2.2) JFB2 (2.3) JFB3 (2.4) 
Compound name macrolactin A Sch 54796 chaetomin 
W2 P. falciparum IC50 = 17 µM IC50 = 60 µM IC50 = 77 µM 
A549 cytotoxicity IC50 = 25 µM Moderately Cytotoxic IC50 = 2 µM 
MRSA 1 MIC = 18 µM Not Active MIC = 4 µM 
MRSA 2 Not Active Not Active MIC = 42 µM 
MRSA 3 Not Active Not Active MIC = 7 µM 
Structure 
 
 
 
Chemist Code JFB4 (2.5) JFB5 (2.6) JFB6 (2.7) 
Compound name beauvericin bostrycoidin-9-methyl ether roquefortine C 
W2 P. falciparum IC50 = 4 µM IC50 = 3 µM Not Active 
A549 cytotoxicity IC50 = 14 µM IC50 = >334 µM IC50 = >357 µM 
MRSA 1 MIC = 38 µM Not Tested MIC = 129 µM 
MRSA 2 Not Active Not Tested MIC = 257 µM 
MRSA 3 Not Active Not Tested MIC = 26 µM 
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Chapter Three. Epigenetic modifications of fungi 
 
3.1. Early work with epigenetic modifiers and development of techniques 
3.1.1. Practice makes perfect 
 
In order to assess the technique as well as practice on a control, an experiment 
was performed emulating a recent publication.1 The basis for selection was the 
test fungus, Apergillus niger, as it is quick-growing and was already in our 
possession in the laboratory. In the study, Fisch used an HDAC inhibitor to 
promote the production of new metabolites in the fermentation. For the 
experiment with our strain of A. niger, the same inhibitor, sodium butyrate, was 
used at two different concentrations (10 µM and 100 µm) in the same media, 
potato dextrose broth (PDB) and at the same time (1 week).  
 
Figure 3.1. LC/MS results of the A. niger experiment. New peaks indicated by red arrows. 
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The effects of the epigenetic modification were observed qualitatively using liquid 
chromatography coupled with mass spectrometry (LC/MS). Peaks not present in 
the control can indicate the activation of silenced genes encoded for the 
production of secondary metabolites. This experiment resulted in additional 
peaks (Figure 3.1) in the epigenetically modified cultures versus the control and 
thus allowed us to move forward with mangrove endophytes. 
 
3.1.2. Trials with mangrove endophytes 
 
After the successful execution of this trial experiment, a second trial was 
performed using three mangrove endophytes from the Everglades 2010 
collection that had previously shown activity against MRSA. The method was 
modified to use SDB instead of PDB as well as shaking the culture vessels for 
three weeks instead of one to accommodate the preference of endophytic fungi. 
The epigenetic modifier, sodium butyrate, remained the same and was added at 
a concentration of 100 µM. For these trials the epigenetic modifications were 
measured in two different ways, qualitatively using LC/MS and quantitatively 
using a disk diffusion bioassay against MRSA. 
 
The results showed that new peaks were present in the epigenetically modified 
cultures compared to the controls (Figures 3.2-3.4). In addition, increased titers 
of certain metabolites were obtained. The molecular mass of each compound 
was checked in the control versus the modified cultures to ensure that they were 
either the same compound or indeed new. 
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Figure 3.2. LC/MS results from fungus EG10-02C-1. The red arrow indicates new peaks while 
the blue arrow indicates an increased quantity of one of the metabolites. 
 
 
Figure 3.3. LC/MS results from fungus EG10-18B-2. Red arrows indicate new peaks; the blue 
arrow indicates an increased quantity of one of the metabolites, while the green arrow indicates a 
metabolite produced in decreased quantity. 
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Figure 3.4. LC/MS results from fungus EG10-20D-2. Red arrow indicate new peaks while the 
blue arrow indicates an increased quantity of one of the metabolites. 
 
In the figures above, a red arrow indicates a new peak with a different mass and 
the blue arrow depicts the same compound as the control but in greater quantity. 
It is interesting to note that in Figure 3.3 one metabolite had a dominating 
presence (indicated by the green arrow) in the control culture. However, in the 
modified culture, that compound was in smaller quantity, but perhaps as a result, 
the metabolites in the 10 to 12 minutes range were in greater quantity. 
 
The antibiotic susceptibility assay also provided some interesting information. 
The extracts from the control and modified cultures were tested against a two 
Gram-positive bacteria, MRSA-3 and Bacillus subtilis, and two Gram-negative 
bacteria Pseudomonas aeruginosa and Klebsiella pneumonia. In this experiment 
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MRSA-3 was utilized as the control since the fungi were already known to 
produce compounds active against the pathogen. 
 
Table 3.1. Bioassay results using crude extracts of both epigenetically modified fungi as well as 
their controls. Results are indicated as ZOI in millimeters from edge to edge. 
 
 MRSA-3 B. subtilis P. aeruginosa K. pneumoniae 
EG10-02C-1 12 mm N N N 
EG10-02C-1 Mod 18 mm N 7 mm N 
EG10-18B-2 16 mm N N N 
EG10-18B-2 Mod 26 mm N 8 mm N 
EG10-20D-2 14 mm N N N 
EG10-20D-2 Mod 14 mm N 8 mm N 
 
The bioassay showed that the activity against MRSA-3 increased in the 
epigenetically modified fungi EG10-02C-1 and EG10-18B-2 and remained the 
same with fungus EG10-20D-2. In addition, all three exhibited new activity, albeit 
weak, against P. aeruginosa in the modified cultures versus their controls. This 
experiment, similarly to the LC/MS trials, was successful in supporting the 
hypothesis that increased or new activity can arise from the addition of the 
epigenetic modifiers in the fermentation. 
 
3.2. Epigenetic modification studies with fungus Leucostoma persoonii 
3.2.1. Experimental design 
 
The fungus EG10-18B-2 was isolated from red mangrove branch bark obtained 
from the Florida Everglades in the summer of 2010.  Analysis of the 
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18S ribosomal RNA gene by BLAST database provided a 99% match to 
Leucostoma persoonii. This isolate of L. persoonii exhibited several points of 
interest. First, the extract demonstrated >50% inhibition at 50 µg/mL against 
P. falciparum. Next, it was found to be active against MRSA with a ZOI of 16 mm. 
Finally, in our preliminary experiments with epigenetic modifications the activity 
against MRSA increased, and new activity against P. aeruginosa was observed. 
This stimulated our interest in further research with epigenetic modifications with 
this fungus at large scale. Two types of modifications were attempted and for 
each, several prospective inhibitors were considered. The DNMT inhibitors 
evaluated were 5-azacitidine (3.1), 5-aza-2'-deoxycytidine (3.2), hydralazine (3.3) 
procaine (3.4) and procainamide (3.5).  
                     
      3.1. 5-azacitidine                      3.2. 5-aza-2'-deoxycytidine              3.3. hydralazine 
   
                         3.5. procaine                                                       3.5. procainamide 
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The HDAC inhibitors studied were sodium butyrate (3.6), suberohydroxamic acid 
(3.7), valproic acid (3.8), trichostatin A (3.9) and trapoxin B (3.10).  
            
         3.6. sodium butyrate                                       3.7. suberohydroxamic acid 
          
     3.8. valproic acid                                                            3.9. trichostatin A 
 
3.10. trapoxin B 
 
A survey of the literature showed that the most commonly used DNMT inhibitor 
was 5-azacitidine and the most commonly used HDAC inhibitor was sodium 
butyrate. Those two were selected and evaluated for optimal concentration, as 
well as incubation time. It is interesting to note that different groups greatly differ 
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in regards to concentration of the modifiers. For example, one group performed 
MIC assays on the fungi to be epigenetically modified and then used a 
concentration tenfold lower than their MICs,2 thereby utilizing high 
concentrations. In another study, a series of concentrations (10, 50, 100, 
200 µM) were tested and it was determined that the most effective one was mid-
range, over 50 µM.3 Finally, yet another study tested low and high concentrations 
on a carotene-producing fungus. They determined that at concentrations less 
than 30 µM they achieved increased production of the carotenes but that at high 
levels 100-300 µM, the fungus showed a decrease in production.4 Consequently, 
our fungus was subjected to the following experimental conditions: 
 
• DNMT inhibition, HDAC inhibition, a combination of both. 
• Concentrations of 1, 10, 50, 100 and 500 µM 
• Incubation time of 7, 14 and 21 days. 
 
The fermentations for these experiments were all performed in triplicate 
alongside controls to insure accurate data and repeatability. Plugs of agar 
containing mycelia from small-scale cultures of the fungus were placed into 
vessels containing 125 mL of sterile SDB. The vessels were then placed on a 
rotary shaker and shaken at 20 rpm for 48 h at room temperature. Next an 
aliquot of the epigenetic modifier was added to reach appropriate final 
concentrations of 1-500 µM, to achieve the desired dose-response 
concentrations. After this addition, vessels were shaken for an additional 5-
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19 days, to achieve the desired final incubation times. The resulting cultures 
were lyophilized and extracted in MeOH. All biological assays and chemical 
experiments for the epigenetic experiments were performed with these extracts. 
 
3.2.2. Results and optimal conditions 
 
As shown in Figure 3.5, the bioassay revealed that the maximal zone of inhibition 
against MRSA-3 was obtained using a concentration of 50 µM of the DNMT 
inhibitor and a concentration of 100 µM of the HDAC inhibitor. 
 
 
Figure 3.5. Average of triplicate ZOI determinations against MRSA-3 for the crude methanol 
extract of Leucostoma persoonii at each concentration of epigenetic modifier. The sterile disks 
measure 6 mm, thus a result of 6 mm indicates no inhibition at that concentration. 
 
Subsequent time-course experiments, using the previously identified optimal 
inhibitor concentrations, indicated that the HDAC-inhibited culture exhibited 
activity as early as week one with a maximum at week two, while the DNMT-
inhibited culture and control required three weeks to achieve maximal activity 
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(Figure 3.6). Interestingly, it seemed that the DNMT inhibitor slowed the 
production of the active compounds until week 3. 
 
 
Figure 3.6. Average of triplicate ZOI determinations against MRSA-3 for the crude at each time 
point of incubation of Leucostoma persoonii. The sterile disks measure 6 mm, thus a result of 6 
mm indicates no inhibition at that concentration. 
 
A noteworthy observation was the striking differences in colony morphology in 
the treated vs untreated cultures (Figure 3.7). Interestingly, experiments in which 
we combined the DNMT and HDAC inhibitors produced inconsistent results, with 
some replicate cultures more active and others completely inactive. Overall, it 
was found that the best experimental conditions required the HDAC inhibitor and 
an incubation time of two weeks. The experiments using a combination of both 
the HDAC and DNMT inhibitors proved to be unreliable across replicates. 
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Figure 3.7. The control culture of Leucostoma persoonii (left) shows a pale yellow color at week 
one and two time points while the HDAC-inhibited culture (right) shows a darker yellow and brown 
coloration at the same time points 
 
LC/MS analyses of culture extracts were found to corroborate the MRSA activity 
profiles in all cases. For example, in the time experiment control cultures showed 
that several peaks in the 10 min to 15 min region (Figure 3.8) began to appear at 
the 14-day mark while other peaks appeared only after 21 days. This was an 
exact match of the bioactivity profile. Another example, in the dose-response 
experiment for the DNMT inhibitor, several peaks in the highlighted region 
(Figure 3.9) boast greater areas at the 50 µM concentration versus other peaks. 
In addition, certain peaks appear to be present in chromatograms from the 
50 and 100 µM DNMT inhibitor that are absent at other concentrations. This 
indicates the presence of potential new compounds produced only by the 
addition of the epigenetic modifier in the fermentation. 
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Figure 3.8. Overlay of LC/MS total ion chromatograms (TIC) from each time point of crude 
extracts of control cultures of Leucostoma persoonii. Region highlighted indicates varying levels 
of the peaks of interest matching the bioactivity profile. 
  
 
Figure 3.9. Overlay of LC/MS total ion chromatograms (TIC) from each concentration of crude 
extracts of DNMT-inhibited cultures of Leucostoma persoonii. Region highlighted indicates 
varying levels of the peaks of interest. 
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3.3. Isolation of the principal components of Leucostoma persoonii 
3.3.1. Principal components 
 
The methanol extract (1.3 g) of the lyophilized culture was first fractionated on 
normal phase MPLC and the active fraction purified via HPLC to afford pure 
cytosporones A (JFB-12, 3.11), B (JFB-9, 3.12), C (JFB-8, 3.13) and E (JFB-7, 
3.14) as well as comazaphilone D (JFB15, 3.15) with the following masses of 0.6 
mg, 1.1 mg, 0.5 mg, 1.9 mg and 3.4 mg respectively (Figure 3.10). The 
compounds were identified and matched to literature data (Tables 3.2-3.3)5,6 
using low resolution mass spectrometry and 1H and 13C NMR spectroscopy.  
 
 
Figure 3.10. Isolation scheme for cytosporones and comazaphilone D from L. persoonii. 
A                B                C               D                E                F
1                  2                  3                 4                    5                   6
L. persoonii extract (1.3 g)
Silica MPLC – Hexane – EtOAc – MeOH
C18 HPLC – Water – ACN
Cytosporone E
1.9 mg
632 mg        24 mg        84 mg       105 mg        248 mg      137 mg
3.5 mg         1.1 mg          1.4 mg       5.4 mg          2.1 mg          0.2 mg
Cytosporone C
0.5 mg
Cytosporone A
0.6 mg
Cytosporone B
1.1 mg
Comazaphilone D
3.4 mg
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          3.11. cytosporone A                                       3.12. cytosporone B 
 
 
 
                    
3.13. cytosporone C                                       3.14. cytosporone E 
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Table 3.2. Comparison of JFB7, 8, 9 and 12 with cytosporone A, B, C and E5 
JFB12 cytosporone A JFB9 cytosporone B 
1Ha 13Cb 1Hc 13Cd 1Ha 13Cb 1Hc 13Cd 
6.24 (d) 206.0 6.36 (s) 207.5 6.27 (d) 207.7 6.37 (d) 206.3 
6.22 (d) 172.7 6.34 (s) 172.5 6.20 (d) 172.2 6.31 (d) 171.6 
3.56 2H, s) 159.0 3.64 (2H, s) 161.0 4.11 (2H, q) 159.9 4.08 (2H, q) 160.7 
2.92 (2H, t) 157.1 2.94 (2H, t) 160.1 3.57 (2H, s) 158.4 3.67 (2H, s) 159.7 
1.62 (m) 136.4 1.63 (p) 137.6 2.90 (2H, t) 135.6 2.90 (2H, t) 137.0 
1.24-1.36 (8H, m) 120.4 1.27−1.30 (8H, m) 120.5 1.60 (p) 119.9 1.63 (p) 120.8 
0.89 (t) 109.9 0.86 (3H, t) 111.7 1.26-1.32 (8H, m) 110.3 1.26−1.32 (8H, m) 111.8 
 
101.0   102.5 1.24 (3H, t) 101.4 1.21 (3H, t) 102.5 
 
43.5   44.4 0.90 (3H, t) 60.5 0.88 (3H, t) 61.0 
 
31.2   40.6   43.8   44.4 
 
28.8   32.5   39.1   40.1 
 
28.7   30.0   31.5   32.5 
 
23.8   29.9   29.1   30.0 
 
22.1   25.1   28.9   29.9 
 
22.1   23.3   24.2   25.0 
 
14.0   14.3   22.3   23.3 
  
  
 
  13.1   14.5 
          13.0   14.3 
JFB8 cytosporone C JFB7 cytosporone E 
1Ha 13Cb 1Hc 13Cd 1Ha 13Cb 1Hc 13Cd 
6.22 (d) 174.1 6.34 (s) 170.5 6.78 (s) 170.5 6.83 (s) 170.9 
6.13 (d) 159.6 6.23 (s) 159.0 5.46 (dd) 147.6 5.46 (dd) 147.6 
5.60 (dd) 155.2 5.55 (dd) 154.5 2.24 (m) 139.9 2.24 (m) 140.5 
3.77 (d) 132.8 3.79 (d) 133.5 1.72 (m) 139.6 1.72 (m) 139.5 
3.46 (d) 113.9 3.45 (d) 114.0 1.26-1.33 (10H, m) 129.1 1.23−1.44 (10H, m) 130.3 
1.84 (m) 106.0 1.86 (m) 106.3 0.89 (3H, t) 115.5 0.87 (3H, t) 118.1 
1.79 (m) 102.0 1.78 (m) 101.8   101.7 
 
102.8 
1.53 (td) 80.1 1.55 (m) 78.3   79.2 
 
80.0 
1.44 (td) 36.7 1.42 (m) 36.4   32.4 
 
33.8 
1.24-1.39 (8H, m) 35.5 1.27−1.30 (8H, m) 35.4   31.2   32.5 
0.90 (3H, t) 32.9 0.86 (3H, t) 32.5   29.0   30.6 
 
30.3   29.9   28.7   29.9 
 
30.2   29.9   24.2   25.4 
 
26.6   26.4   22.0   23.3 
 
23.7   23.3   13.9   14.3 
  14.4   14.3         
aRecorded at 500 MHz in CD3OD, bRecorded at 125 MHz in CD3OD, cRecorded at 
500 MHz in Acetone-d6, dRecorded at 125 MHz in Acetone-d6 
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Table 3.3. Comparison of JFB15 with comazaphilone D6 
 
JFB15 Comazaphilone D 
Position 1Ha 13Cb 1Ha 13Cb 
1 5.08 (dd) 64.0 5.09 (d) 63.8, CH2 
 
4.79 (d) 
 
4.77 (d) 
 3 
 
161.5 
 
161.5, C 
4 5.23 (s) 103.3 5.23 (s) 103.1, CH 
4a 
 
148.5 
 
148.5, C 
5 2.96 (2H, m) 32.3 2.96 (dd) 32.2, CH2 
 
2.78 (d) 
 
2.78 (dd) 
 6 5.63 (t) 76.3 5.63 (t) 76.2, CH 
7 
 
74.3 
 
74.3, C 
8 
 
195.6 
 
195.5, C 
8a 
 
112.8 
 
112.7, C 
9 1.46 (3H, s) 24.4 1.46 (s) 24.2, CH3 
10 5.89 (dd) 124.6 5.89 (d) 124.5, CH 
11 6.51 (dq) 135.7 6.51 (dq) 135.6, CH 
12 1.87 (3H, m) 18.7 1.87 (d) 18.4, CH3 
1' 
 
105.4 
 
105.2, C 
2' 
 
165.7 
 
165.6, C 
3' 6.22 (d) 101.4 6.21 (d) 101.3, CH 
4' 
 
160.9 
 
160.9, C 
5' 6.11 (d) 111.6 6.10 (d) 111.5, CH 
6' 
 
144.2 
 
144.0, C 
7' 2.18 (3H, s) 24.4 2.13 (s) 24.2, CH3 
8' 
 
170.9 
 
170.7, C 
OH 11.53 (s) 
 
11.50 (s) 
 aRecorded at 500 MHz in CDCl3, bRecorded at 125 MHz in CDCl3 
 
Screening against MRSA-3 established (Table 3.4) minimum inhibitory 
concentrations (MIC), minimum bactericidal counts (MBC) and minimum biofilm 
eradication concentration (MBEC). At MIC, cytosporone B demonstrated a 4.2-
fold reduction in bacterial viability and at twice the MIC, resulted in complete 
killing of the bacteria. Furthermore, at MIC, a 2-fold reduction in biofilm formation 
was observed, and at twice the MIC, 168-fold reduction occurred. At higher 
concentrations, it appears strongly active toward biofilms, which is uncommon for 
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antibiotics; however, cytosporone B is cytotoxic toward A549 cells 
(TI90 = IC90 A549/MIC90 = 6). Cytosporone A and C as well as comazaphilone D 
were found to be inactive against MRSA at low micromolar doses and thus were 
not tested further.  
 
Table 3.4. Bioassay results against MRSA and A549 
 MRSA (µM) A549 (µM) 
Compound MIC MBC90 MBEC90 IC50 IC90 
Cytosporone A (3.11) NAa NTb NTb   
Cytosporone B (3.12) 78 93 110 170 190 
Cytosporone C (3.13) NAa NTb NTb 690 840 
Cytosporone E (3.14) 72 45 39 280 440 
Comazaphilone D (3.15) NAa NTb NTb   
        aNot Active; bNot Tested 
 
Cytosporone E was equipotent against MRSA and methicillin-sensitive S. aureus 
strains (72 µM), indicating the intrinsic drug resistant properties of MRSA strains 
are not helpful in resisting the action of this cytosporone. In effect, the target of 
the compound is something that the broadly drug resistant strains have not 
encountered before and suggestive that there is less likelihood that MRSA 
strains would develop resistance to it over time. In addition, at MIC, it resulted in 
>5000-fold reduction in bacterial viability, indicating it is strongly bactericidal, and 
not just bacteriostatic. The cytosporone E minimum bactericidal count (MBC) is 
significantly below its MIC, further demonstrating developmental potential. 
Finally, the minimum biofilm eradication count (MBEC) assay showed a 183-fold 
reduction in bacterial viability at MIC, demonstrating a particularly potent activity 
for this ultra-resistant strain of MRSA. Cytosporone E is also cytotoxic, but 
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reasonably selective for bacteria relative to mammalian cells (TI90 = 10). 
Cytosporone A, B and C as well as comazaphilone D were inactive toward 
Plasmodium falciparum at the levels tested (up to 10 µg/mL). Cytosporone E, 
however, displayed an IC90 of 13 µM, which represents significant selectivity 
(TI90 = 33) for a moderately potent antimalarial drug.   
 
3.3.2. Epigenetic modifications and the principal components 
 
Using the optimal growth conditions established, two large-scale (10 L) cultures 
were grown; one supplemented with the HDAC inhibitor, and the other, an 
unmodified control culture. The cultures were grown, extracted and processed 
side-by-side, in an identical manner, and yielded similar final crude extract 
masses (3.21 g for the modified culture and 2.94 g for the control). Each culture 
extract was purified first by MPLC, then cytosporone containing fractions subject 
to HPLC purification. Cytosporone A, B, C, E and comazaphilone D were again 
the major components in both cultures, however, they were isolated in 
considerably greater amounts from the HDAC-inhibited fermentation. In the 
control, the fungus produced 0.6 mg of cytosporone A, 2.4 mg of cytosporone B, 
0.7 mg of cytosporone C, 3.6 mg of cytosporone E and 5.3 mg of comazaphilone 
D per 10 L of culture. In the epigenetically modified culture, the fungus produced 
275% more cytosporone A (2.1 mg/10 L), 330% more cytosporone B 
(8.7 mg/10 L), 510% more cytosporone C (3.9 mg/10 L), 820% more cytosporone 
E (32.1 mg/10 L) and 607% more comazaphilone D (35.1 mg/10 L). In addition to 
these production increases, we probed the HDAC-inhibited culture for the 
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presence of compounds not found in the control. Three new peaks were isolated 
and identified. The first two resembled potential dimers of cytopsorones and were 
previously reported as integracin A (JFB10, 3.16) and B (JFB14, 3.17) 
(Table 3.5)7 The third peak, however, was found to be a new cytosporone 
analog, cytosporone R (3.18). Figure 3.11 shows the metabolomics differences 
between the control and modified cultures. 
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Table 3.5. Comparison of JFB10 and JFB 14 with intergracin A and B 
Pos JFB10 integracin A JFB14 integracin B 
 
1Ha 13Cb 1Hc 13Cd 1Ha 13Cb 1Hc 13Cd 
1 6.22 (d) 108.1 6.12 (d) 108.0 6.16 (d) 107.8 6.13 (d) 108.0 
2 
 
156.8 
 
158.9 
 
157.0 
 
158.9 
3 6.22 (d) 100.5 6.06 (t) 100.7 6.13 (t) 100.3 6.05 (t) 100.7 
4 
 
156.8 
 
158.9 
 
157.0 
 
158.9 
5 6.22 (d) 108.1 6.12 (d) 108.0 6.16 (d) 107.8 6.13 (d) 108.0 
6 
 
145.9 
 
146.6 
 
145.7 
 
146.5 
7 2.40 (t) 35.9 2.40 (t) 36.5 2.41 (t) 36.5 2.40 (t) 36.5 
8 1.50 (m) 31.0 1.50 (m) 32.0 1.55 (m) 30.9 1.50 (m) 32.0 
9 1.25 (m) 29.1 1.22 (m) 30.0 1.18 (m) 29.0 1.22 (m) 30.0 
10 1.25 (m) 29.3 1.22 (m) 30.1 1.18 (m) 29.2 1.22 (m) 30.1 
11 1.25 (m) 29.3 1.22 (m) 30.2 1.18 (m) 29.3 1.22 (m) 30.3 
12 1.25 (m) 25.4 1.22 (m) 26.3 1.18 (m) 25.3 1.22 (m) 26.3 
13 1.64 (m) 34.2 1.65 (m) 35.0 1.70 (m) 35.8 1.65 (m) 35.0 
14 5.23 (dt) 76.0 5.21 (pt) 76.8 5.27 (dt) 75.8 5.21 (pt) 76.8 
15 1.64 (m) 36.4 1.62 (m) 37.2 1.70 (m) 37.2 1.62 (m) 37.2 
16 1.25 (m) 18.9 1.30 (m) 19.7 1.37 (m) 18.8 1.30 (m) 19.7 
17 0.89 (t) 14.1 0.87 (t) 14.3 0.87 (t) 14.0 0.87 (t) 14.4 
1′ 
 
172.8 
 
172.5 
 
171.5 
 
172.5 
2′ 
 
105.0 
 
105.5 
 
105.1 
 
105.5 
3′ 
 
165.2 
 
166.3 
 
165.4 
 
166.3 
4′ 
6.25 (d) 101.6 6.19 (d) 101.9 6.22 (d) 101.5 6.19 (d) 101.9 
5′ 
 
161.0 
 
162.8 
 
160.6 
 
162.8 
6′ 
6.32 (d) 111.3 6.23 (d) 111.8 6.29 (d) 110.9 6.23 (d) 111.8 
7′ 
 
148.8 
 
148.7 
 
148.6 
 
149.7 
8′ 
2.81 (t) 36.8 2.78 (m) 37.6 2.84 (t) 36.7 2.81 (m) 37.6 
9′ 
1.50 (m) 32.1 1.50 (m) 33.2 1.55 (m) 32.0 1.50 (m) 33.3 
10′ 
1.25 (m) 29.8 1.22 (m) 30.7 1.18 (m) 29.8 1.22 (m) 30.8 
11′ 
1.25 (m) 29.5 1.22 (m) 30.4 1.18 (m) 29.6 1.22 (m) 30.6 
12′ 
1.25 (m) 29.5 1.22 (m) 30.3 1.18 (m) 29.6 1.22 (m) 30.6 
13′ 
1.25 (m) 25.4 1.22 (m) 26.1 1.18 (m) 25.7 1.22 (m) 26.6 
14′ 
1.50 (m) 34.3 1.45 (m) 35 1.55 (m) 34.1 1.45 (m) 35 
15′ 
4.91 (dt) 75.3 4.82 (pt) 74.6 3.52 (m) 72.4 3.49 (m) 71.8 
16′ 
1.50 (m) 36.6 1.45 (m) 37.2 1.55 (m) 39.6152 1.45 (m) 38.3 
17′ 
1.25 (m) 18.7 1.35 (m) 19.4 1.37 (m) 18.7905 1.35 (m) 19.6 
18′ 
0.92 (t) 14.1 0.90 (t) 14.3 0.92 (t) 14.0769 0.90 (t) 14.6 
1′′ 
 
171.7 
 
171.5 
    
2′ 
2.07 (s) 21.5 1.95 (s) 21.4 
    3′′-
OH 12.20 (s) 
 
11.76 (s) 
 
11.83 (s) 
 
11.77 (s) 
 3×OH 6.63 (s) 
 
6.8 (s) 
 
8.35 (s) 
 
7.08 (s) 
 aRecorded at 500 MHz in CD3OD, aRecorded at 125 MHz in 
CD3OD, cRecorded at 400 MHz in CD3CN, dRecorded at 100 MHz 
in CD3CN 
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Figure 3.11. Overlay of HPLC chromatograms at 325 nm from identical active fractions of the 
HDAC-modified culture of Leucostoma persoonii versus the control. Each was injected at a 
concentration of 150 mg/mL. New peaks are highlighted in the red boxes. 
 
3.3.3. Cytosporone R: isolation and structure elucidation 
 
Cytosporone R exhibited structural features similar to those of cytosporone B 
based on its 1H NMR spectrum (Table 3.6) but the presence of additional proton 
signals in the δ 3.5 – 4.5 region along with MS analysis indicated an increase in 
carbon, hydrogen and oxygen count (HRESIMS m/z 391.1740, C19H28O7Na). 
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Table 3.6. 1H and 13C NMR spectral data for cytosporone R and cytosporone B 
Cytosporone R Cytosporone B 
Position δCa, multb δHc (mult, J in Hz) HMBC Position δCd δHd 
1 173.5, C 
 
2, 17 1 171.6 
 2 40.5, CH2 3.61, s 4 2 40.1 3.67 
3 137.1, C 
 
2 3 137.0 
 4 112.0, CH 6.22, d (2.2) 2, 6 4 102.5e 6.37 
5 161.6, C 
 
4, 6 5 160.7 
 6 102.8, CH 6.27, d (2.2) 4 6 111.8e 6.31 
7 160.0, C 
 
6 7 159.7 
 8 121.1, C 
 
4, 6 8 120.8 
 9 209.1, C 
 
10, 11 9 206.3 
 10 45.2, CH2 2.87, m 11, 12, 13 10 44.4 2.90 
11 25.6, CH2 1.60, br, m 10, 12, 13 11 25.0 1.63 
12 30.5, CH2 1.25-1.36, br, m 
10, 11, 
13, 14 12 30.0 1.26-1.32 
13 30.3, CH2 1.25-1.36, br, m 
11, 12, 
14, 15 13 29.9 1.26-1.32 
14 32.9, CH2 1.25-1.36, br, m 
12, 13, 
15, 16 14 32.5 1.26-1.32 
15 23.7, CH2 1.25-1.36, br, m 13, 14, 16 15 23.3 1.26-1.32 
16 14.4, CH3 0.90, t 14, 15 16 14.3 0.88 
17 66.8, CH2 4.16, dd (11.3, 5.4) 18, 19 17 61.0 4.08 
  
4.08, dd (11.3, 5.4) 18, 19 
  
 
18 71.1, CH 3.84, quin (5.4) 17, 19 18 14.5  
19 64.1, CH2 3.54, m 17, 18    a125 MHz, CD3OD, bCarbon multiplicity, determined by HSQC, c500 MHz, CD3OD, 
dLiterature values in acetone-d6.5 eOriginal publication incorrectly assigned these carbon 
signals. Shown as they should be, reversed, as described in later publication.8 
 
While some correlations from the 2D NMR experiments indicated that the carbon 
backbone, including the aliphatic side chain, was identical to that of cytosporone 
B, other correlations were critical in determining the configuration of the 
additional atoms in the second side chain. Specifically, the HMBC correlations 
from H-2-17 to C-18 and C-19, both oxygen bearing sp3 carbons (δ 71 and 64, 
respectively) showed the departure from the cytosporone B ethyl ester moiety. In 
addition, the HMBC correlations from the methine H-18 to both C-17 and C-19 
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but to no other carbons demonstrated that the side chain ended at C-19 as a 
methylene with a hydroxyl group. Finally, using the molecular formula determined 
by HRMS, all that remained was an oxygen and hydrogen, indicating that C-18 
bore a hydroxyl group as well. Cytosporone R lacked optical rotation, leading us 
to believe it is enantiomeric at C18 and thus racemic.  
 
Figure 3.12. Key HMBC correlations leading to the identification of cytosporone R. 
 
Cytosporone R was found to be inactive against MRSA (MIC = 503 µM) and 
malaria (IC50 > 10 mg/mL). For cytotoxicity, it had an IC50 of 279 µM against 
A549 cells.  
 
3.4. Summary and conclusion 
 
Epigenetic modifications to fungi proved to be an effective technique in 
increasing the titers of secondary metabolites as well as allow for the production 
of compounds not found in untreated cultures. The cytosporones, and in 
particular cytosporone E, demonstrated interesting bioactivity against malaria 
and MRSA. 
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Chapter Four. Structure activity relationship studies of cytosporones 
 
Structure activity relationship (SAR) studies play an important role in drug 
discovery by optimizing a known active compound, propelling it into clinical 
stages. Medicinal chemists modify molecules by making small changes at 
different sites in order to identify pharmacophores, increase activity and/or 
decrease toxicity. An interesting example of drug optimization is presented by 
Danishefsky’s conversion of the anticancer lead epothilone B (EpoB) (4.1) into 
fludelone (4.2)1. Epothilone B is a natural product isolated from the 
myxobacterium Sorangium cellulosum with an anticancer mechanism of action 
similar to Taxol.2 The group had noticed that in early animal models it was highly 
toxic, even at sub-therapeutic levels. Initially, the group hypothesized that the 
epoxide at the C12-C13 position was responsible for the toxicity and thus 
eliminated it (Scheme 4.1). The resulting compound, dEpoB (4.3) was found to 
be much less toxic to mice but the anticancer potency was also drastically 
reduced.1 Continuing with optimization, the group hypothesized that adding 
rigidity in the molecule by creating a second olefin at the C9-C10 position would 
make a more potent candidate. As suspected, the modification led to 9,10-
dehydro-dEpoB (4.4), with greatly increased anticancer activity in animal 
models.1 Unfortunately with greater activity arose greater toxicity. The group thus 
attempted several more modifications leading to the trifluoromethyl analogue, 
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fludelone. This compound had greatly reduced toxicity as well as broadened 
therapeutic uses. This drug is currently in preclinical development and has also 
been further optimized for specific uses.1 It is a great success that highlights the 
importance of drug optimization through SAR studies. 
 
 
Scheme 4.1. The pathway and reasoning from EpoB to fludelone as described by Wilson et al.1 
 
4.1. Bioactivity profile of the natural products 
 
The cytosporones isolated from the fungus Leucostoma persoonii were screened 
against malaria and MRSA-3, as well as against human cells for cytotoxicicty. 
The biological data acquired for the natural products was used to guide initial 
SAR studies. The molecules can be divided into two groups: one represented by 
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cytosporone A, B and R, with an ester side chain; and the other represented by 
cytosporone C and E, where instead of this side chain, a lactone is present. 
(Figure 4.1)  
 
 
Figure 4.1. Summary of the biological activity of the isolated cytosporones. 
 
The differentiating factors of the first group are limited to the ester side chain. 
Cytosporone A, B and R terminate with an acid, an ethyl ester and a 
monoglyceride, respectively. While all three were found to be inactive against 
P. falciparum, cytosporone B exhibited moderate activity against MRSA 
indicating the importance of the ethyl ester moiety. The second group 
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differentiates in two ways: the number of hydroxyl groups on the benzene ring 
(two for cytosporone C and three for cytosporone E) as well as the lactone ring 
size (6-membered for cytosporone C and 5-membered for cytosporone E). The 
activity varies greatly between the two analogs in that cytosporone C is inactive 
and cytosporone E is moderately active in both assays. At this point it is difficult 
to understand which factors are responsible for the activity. Comparing the active 
molecules from each groups, cytosporone E stands out as the best candidate for 
SAR due to its activity against malaria, unique amongst the isolated 
cytosporones and though equipotent against MRSA with cytosporone B, it has 
less cytotoxicity. 
 
4.2. Previous synthetic routes for cytosporone E 
4.2.1. Total synthesis of cytosporone E: pathway 1 
 
Ohzeki and Mori first described the total synthesis of cytosporone E in 2003.3 
The pathway to the natural product involved three key steps (Scheme 4.2): 
Miyaura-Suzuki coupling (4.7-4.8)4, Sharpless asymmetric dihydroylation (4.8-
4.9)5 and Barton radical deoxygenation (4.9-4.11)6. The synthesis needed nine 
overall steps and chrial HPLC to obtain enantiomerically pure cytosporone E with 
an overall yield of 11%. The goal of the research was to determine whether the 
enantiomers exhibited increased activity versus the racemic mixture. After 
synthesizing the compounds and testing them against a panel of fungi 
(Candida sp. and Aspergillus sp.) they determined that the activity of the 
separate enantiomers was indistinguishable from that of the racemates. This 
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synthetic pathway, though interesting, possessed a few challenges for a SAR 
study: the overall yield is low and the building blocks involved making analogs 
that were not commercially available and would have required several more 
steps to complete. 
 
Scheme 4.2. The Ohzeki and Mori total synthesis and resolution of enantiomerically pure (R)-
cytosporone E. The step between 4.8 and 4.9 uses an asymmetric catalyst to achieve desired 
enantiomer (AD-mix-α yields (S) and AD-mix-β yields (R) products). 
 
4.2.2. Total synthesis of cytosporone E: pathway 2 
 
Fortunately, another group led by Wyatt developed a simpler and quicker route 
for the synthesis of cytosporone E with an overall yield of 44%.7 (Scheme 4.3) 
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The natural product was produced in six steps using the Meyers ortho-alkylation 
of chiral phthalides.8 The method beings with a benzoic acid substrate (4.13) and 
coupling it with L-valine methyl ester hydrochloride using the peptide coupling 
reagents9 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (EDC) 
and 1-hydroxybenzotriazole hydrate (HOBt) in the presence of triethylamine to 
make the ethyl ester product (4.14). This was thought to be a key step in forming 
analogues of cytosporone E as a multitude of benzoic acids are commercially 
available and can be substituted for 3,4,5-trimethoxybenzoic acid. 
 
 
Scheme 4.3. Total synthesis of cytosporone E by Wyatt et al.7 
 
The ester was then reduced to the primary alcohol (4.15) using lithium 
borohydride. Next, the oxazoline (4.16) was formed using methanesulfonyl 
chloride in triethylamine. The oxazoline (4.16) was then subjected to Meyers 
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ortho-alkylation using sec-butyllithium (sec-BuLi) to lithiate the benzene ring and 
then coupling it with the aldehyde n-octanal creating the intermediate alcohol 
(4.17). The reaction was worked up with saturated NH4Cl, promoting the 
rearrangement described by Meyers8 and yielding a racemic mixture of the imino 
lactone (4.18). This was again thought of as a critical step in synthesizing 
cytosporone E analogues because many aldehydes are commercially available 
and can be substituted for n-octanal, yielding final products with different side 
chains. The newly cyclized product (4.18) was then hydrolyzed using 
hydrochloric acid yielding the phthalide product (4.19). This final intermediate 
was then deprotected using boron tribromide to afford a racemic mixture of 
cytosporone E. 
 
4.3. Method development for improvement of the total synthesis 
 
While Wyatt et al.’s method was well designed, some of the steps proved to be 
problematic in synthesizing our target analogues. This subchapter summarizes 
our optimizations. 
 
4.3.1. Step 4: Alkylation 
 
The Meyers ortho-alkylation step in particular proved to be unreliable with some 
aldehydes. Research into the original publication8 revealed that several other 
organolithium reagents were suitable in beginning the reaction. Two others, 
methyllithium (MeLi) and n-butyllithium (n-BuLi) were attempted in tandem with 
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the original reagent, sec-BuLi at two different concentrations with the oxazoline at 
a 50 mg scale. The reaction time was reduced from 6 hours to 30 minutes from 
the lithiation step and from overnight to 2 hours for the alkylation step. The 
results (Table 4.1) showed that the sec-BuLi at an equivalence of 1.2 yielded 
11.4 mg of product, a 16% yield and at an equivalence of 2.4, it yielded 35.7 mg 
of product, a 49% yield. The n-BuLi afforded 37.9 mg of product, a 52% yield. 
MeLi yielded no product. In addition to being more versatile across analogues as 
noted in later experiments, the new methodology greatly reduces the reaction 
time as using n-BuLi takes only 30 minutes to lithiate and 2-3 hours to alkylate 
depending on the aldehyde. Finally, the workup step using a mild acid for 
rearrangement into the lactone was changed to deionized water rather than 
saturated NH4Cl as it was equally effective. 
 
Table 4.1. Comparison of different organolithium reagents in the Meyers ortho-alkylation step. 
 
Reagent Equivalents Product (mg) Yield (%) 
sec-BuLi 1.2 11.4 16 
sec-BuLi 2.4 35.7 49 
n-Buli 1.2 37.9 52 
MeLi 1.2 0 0 
 
4.3.2. Step 6: Deprotection 
 
The last step, deprotection of the methyl esters by boron tribromide also proved 
to be problematic with some of the analogues degrading during the procedure 
leading us to search for a milder technique. Iodocyclohexane has recently 
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become a popular choice for deprotecting aryl methyl esters due to its gentle 
generation of hydroiodic acid in situ. Zuo described the technique in 2008, 
generating high yields, generally in the 90% range, in just 3-8 hours on 
average.10 The method also demonstrated that multiple methyl groups could be 
cleaved by increasing the reagent to 5 equivalents for each methoxy group. This 
technique was tested using the protected precursor to cytosporone E and was 
successful with a yield of 94%. This was slightly better than the original method 
and was proven in later experiments to be effective and more versatile with the 
other analogues, where boron tribromide previously failed. 
 
4.3.3. Final improved methodology for cytosporone E SAR 
 
The revised synthetic route to cytosporone E is summarized in Scheme 4.4. 
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Scheme 4.4. Revised synthetic route to form cytosporone E. 
 
4.4. Cytosporone E analogs 
 
With a more rugged methodology in place for the formation of cytosporone E, the 
synthesis of analogues was undertaken with two specific areas of interest. From 
the cytosporone E skeleton the areas that were considered for investigation were 
A: the substituents on the aryl ring and B: the alkyl side chain. (Figure 4.2) 
 
 
Figure 4.2. Areas of interest for structural modifications of SAR study. A indicates substituents to 
the aryl ring and B the side chain to be modified. 
 
4.4.1. Ring substitutions 
 
To get a baseline for the experiment, both stearic and electronic effects were 
studied. Using the improved synthetic pathway (Scheme 4.5), the first compound 
formed was the trimethoxy analogue (4.19, JFB16). This analogue represented 
electron-donating moiety. Next, the synthesis was attempted using the 3,4,5-
trifluorobenzoic acid (4.20) starting material leading to the trifluoro analogue 
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(4.21: JFB-18), an electron-withdrawing version. Also attempted, using the 3,4,5-
trimethylbenzoic acid (4.22) starting material leading to the trimethyl analogue 
(4.23: JFB-19), both electronically neutral and stearically hindered. Finally, the 
synthesis was accomplished using benzoic acid (4.24) to afford an aryl ring 
without substituents, representing an analogue (4.25: JFB-17) that is neither 
stearically hindered nor has electronic effects. 
 
Scheme 4.5. Synthesis of aryl ring analogues of cytosporone E. 
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4.4.2. Side chain substitutions 
 
The side chain analogues were approached by observing differences in length 
and functionality. Starting from the oxazoline (4.16) a substitution of the aldehyde 
provided side chain analogues (Scheme 4.6). The first was attempted using 
actetylaldehyde (4.38) in order to produce an analogue with a methyl group 
(4.39: JFB-20) instead of the bulky 7-membered alkyl chain. Next, the method 
was repeated using benzaldehyde (4.40), yielding the benzyl side chain 
analogue (4.41: JFB-21). It was selected due to its versatility as the ring can later 
be functionalized akin to studies in the previous section to optimize the aryl ring. 
Finally, an analogue was formed using hexanal (4.42), affording the truncated 5-
membered side chain analogue (4.43: JFB-22). It was selected to determine 
whether the entire chain is necessary for activity or if it can be shortened. 
 
 
Scheme 4.6. Partial synthetic scheme of side chain analogues of cytosporone E from oxazoline. 
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4.5. Biological activity summary and discussion 
4.5.1. Antiplasmodial activity 
 
Though the amount of synthetic analogues prepared was limited, this study 
offered some very important clues to understand the activity profile of this 
structure. For example, the compounds synthesized to investigate electronic and 
stearic effects on the aryl ring, though extreme compared to each other, proved 
to be similar in activity (Table 4.2). This indicates that this particular portion of the 
molecule does not play a significant role in the activity against P. falciparum. 
However, the analogues with varied side chains demonstrated noteworthy 
differences. The analogue with the partially truncated 5-membered chain (4.43) 
was very similar in activity as the natural product, while the methyl analogue 
(4.39) was more than 10-fold less potent. Furthermore, the analogue with the 
benzene ring was completely inactive at the levels tested. This indicated that the 
activity is strongly related to this 7-membered aliphatic side chain. A recent 
example in literature, cladosporin (4.50), supports this observation. The fungal 
metabolite proved to be a potent inhibitor of Plasmodium parasites at nanomolar 
levels.11 Caldosporin is very similar in structure to cytosporone E in that it 
consists of a phenol-subsitituted aryl ring fused to a lactone with a 7-membered 
carbon chain. The major difference with cladosporin is that the side chain is 
arranged in a 6-membered lactone ring. Yet this minor difference results in a 
significant increase in activity. Thus the number of carbons and their 
configuration plays a meaningful role in the bioactivity of the molecule and further 
work with this study should focus on cyclic arrangements for the side chain. 
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Table 4.2. Summary of anti-plasmodial activity and cytotoxicity of cytosporone E and analogues. 
 
Compounds P. falciparum IC50 A549 IC50 
 
Cytosporone E 
8 µM 280 µM 
 
4.19 
18 µM 139 µM 
 
4.21 
34 µM 188 µM 
 
4.23 
44 µM 157 µM 
 
4.25 
36 µM 118 µM 
 
4.39 
151 µM >255 µM 
 
4.41 
> 194 µM >194 µM 
 
4.43 
27 µM 158 µM 
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4.50 – cladosporin 
 
4.5.2. Antibiotic activity 
 
 
The antibiotic assays revealed some interesting results (Table 4.3). Against 
MRSA, nearly all the analogues lost activity. The only analogue that showed 
inhibition was 4.43 with a partially truncated side chain. This was the closest 
analogue to the natural product, hence not much can be concluded from this 
limited SAR study against MRSA. However, testing against other bacterial 
pathogens revealed some interesting results. Across all bacteria tested, the 
analogues in which the aryl ring substituents were varied, the activity was lost. 
However, some differences were seen in the side chain substitutions. The 
analogue with the completely truncated side chain in 4.39 proved to be inactive, 
but the 5-membered side chain (4.43) analogue showed to be a little more active 
than the natural product and the benzene ring side chain analogue (4.41) was 
the most active. These results are interesting because thought the compounds 
appear to have more broad-spectrum activity, the cytotoxicity results as shown in 
Table 4.2 demonstrated that the mentioned active analogues were overall equal 
or less toxic to human cells than the natural product, indicating a selective 
antibiotic activity. Furthermore, the benzene ring analogue was the most active 
O
O
H
HO
OH O
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and that is interesting because this new ring can be functionalized with electron 
donating/withdrawing groups to further increase activity. 
 
Table 4.3. Summary of antibiotic activity of cytosporone E and analogues. 
 
Compounds MRSA MIC S. aureusa B. subtilisa M. luteusa A. baumanniia 
 
Cytosporone E 
72 µM 8 mm 8 mm 12 mm 16 mm 
 
4.19 
>621 µM NAb NAb 7 mm NAb 
 
4.21 
>862 µM NAb NAb NAb NAb 
 
4.23 
>699 µM NAb NAb NAb 8 mm 
 
4.25 
>730 µM NAb NAb 8 mm NAb 
 
4.39 
>1020 µM 10 mm NAb 10 mm  9 mm 
 
4.41 
>775 µM 12 mm 14 mm 16 mm 26 mm 
 
4.43 
595 µM 12 mm 10 mm 12 mm 22 mm 
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4.6. Conclusion 
 
The synthetic pathway to cytosporone E and its analogues was improved from 
previous work with a more versatile methyllithium reagent as well as a more 
gentile and effective deprotection method using iodocyclohexane.  In total, seven 
analogues were prepared including electron withdrawing/donating groups as well 
as shortening the side chain. Though none of the analogues were as potent as 
the natural product thus far, they did offer a clue into the importance of the 
aliphatic side chain, and coupled with literature precedents, this study showed 
some potential in more analogues to be synthesized in the future to further 
improve this molecule. 
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Chapter Five. Experimental 
 
5.1. General procedures and techniques 
 
Optical rotations were measured on a Rudolph Research Analytical 
AUTOPOL IV digital polarimeter. IR and UV spectra were measured on a 
Nicolete Avatar 320FT infrared and a Hewlett-Packard 8452A diode array 
spectrophotometer, respectively. Medium pressure liquid chromatography was 
carried out on a Teledyne Isco Combiflash Companion using normal and reverse 
phase silica Gel and C18 cartridges, respectively, purchased from Teledyne Isco. 
High performance liquid chromatography was carried out on semipreparative 
Phenomenex Luna C18 (2) reverse phase (250 × 10 mm) or Luna Silica (2) 
normal phase (250 × 10 mm) and analytical (250 × 4.6 mm) columns using a LC-
20A Shimadzu multi-solvent delivery system, a CBM-20A Shimadzu system 
controller, and a SPD-M20A Shimadzu PDA detector. Low resolution mass 
spectra were recorded on an Agilent Technologies LC/MSD VL electrospray 
ionization mass spectrometer. High resolution mass spectra were recorded on an 
Agilent Technologies LC/MSD TOF electrospray ionization spectrometer. 1H and 
13C NMR spectra were recorded on a Varian Inova instrument operating at 
500 MHz for 1H, 126 MHz for 13C using standard pulse sequences as well as 
using residual protonated solvent as 1H internal standard or 13C absorption lines 
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of solvents for 13C internal standard. All shifts were measured in ppm and 
coupling constants in Hz. 
 
Methicillin-Resistant Staphylococcus aureus strains. MRSA-1: This strain of 
MRSA was identified from the vendor as ATCC-33592. It was obtained from 
Presque Isles Cultures P.O. Box 8191, Erie, PA 16505. MRSA-2: This strain of 
MRSA is a community-associated clone from the CDC USA300 lineage. It was 
isolated from the Los Angeles County Jail and found to be highly aggressive, with 
fatalities recorded within 72 hours of infection. MRSA-3: This strain of MRSA is a 
hospital-associated clone from the CDC USA100 lineage. It was isolated from 
Tampa General Hospital and was found to be broadly resistant to a variety of 
antimicrobials, including: methicillin, centhromycin, azithromycin, erythromycin, 
clindamycin, ampicillin, chloramphenicol, gentamicin, tetracycline, ciprofloxacin; 
as well as intermediary resistance to daptomycin, linezolid and vancomycin. It is 
thus deemed an extensively drug resistant strain, and something of a worst-case 
scenario MRSA isolate. 
 
Disk diffusion assay. The bacteria was collected from glycerol stocks and 
streaked onto TSA and incubated for 24 h at 37 °C. A 250 mL Erlenmyer flask 
containing 75 mL of TSB was inoculated with a single colony from the TSA plate 
and incubated for 24 h at 37 °C. The resulting culture was diluted 1:1,000 into 
melted TSA at 50 °C and the resulting mix was poured into Petri dishes at a 
volume of 5 mL. While the agar solidified, 20 µL of the test extract or fraction was 
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applied to the center of the disks from a 50 mg mL−1 stock (for crudes) or 5 mg 
mL−1 stock  (for fractions) in MeOH and allowed to dry. The disks were then 
placed onto the inoculated Petri dishes and then the plates were incubated at 
37 °C for 24 h. Assays performed in triplicate and the results were measured in 
as a zone of inhibition (ZOI) if present.  The ZOI represents the diameter of the 
inhibitory area in mm. 
 
Microtiter MIC and MBC determination assays. The minimum inhibitory 
concentration (MIC) of the pure compounds was determined as follows. The 
bacteria was collected from glycerol stocks and streaked onto TSA and 
incubated for 24 h at 37 °C. A 250 mL Erlenmyer flask containing 75 mL of TSB 
was inoculated with a single colony from the TSA plate and incubated for 24 h at 
37 °C. These were diluted 1:1,000 with TSB and 200 µL was pipetted into each 
well a sterile 96-well plate. Pure compounds were diluted in DMSO and then 
mixed into the wells at decreasing concentrations. The well plates were the 
incubated for 24 h at 37 °C. The MICs were detected visually by the lack of 
turbidity in the well (indicating a lack of bacterial growth at those concentrations). 
Assays were performed in triplicate, with DMSO as the control. After the MIC was 
complete, the minimum bactericidal concentration (MBC) counts were performed 
from those same cultures. The media from each well was diluted to a series of 
concentrations and then plated onto TSA. The Petri dishes were incubated for 
24 h at 37 °C. The resulting colonies were counted resulting in a total bacterial 
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load. The drug-containing wells were compared to the control wells giving a 
percentage killing rate for the MBC. 
 
5.2. Experimental supporting Chapter 2 
 
Bostrycoidin-9-methyl ether. The X-ray diffraction data were collected using a 
Bruker-AXS SMART-APEXII CCD diffractometer (CuKα, λ = 1.54178 Å). Crystal 
data and refinement conditions are shown below. 
 
Crystal data and structure refinement for compound JFB5 
Identification code             
Empirical formula               
Formula weight                  
Temperature                     
Wavelength                      
Crystal system, space group     
Unit cell dimensions            
                                
                                
Volume                          
Z, Calculated density           
Absorption coefficient          
F(000)                          
Crystal size                    
Theta range for data collection 
Limiting indices                
Reflections collected / unique  
Completeness to theta = 65.06   
Absorption correction           
Max. and min. transmission      
Refinement method               
Data / restraints / parameters  
Goodness-of-fit on F^2          
Final R indices [I>2sigma(I)]   
R indices (all data)            
Largest diff. peak and hole 
JFB5 
C17 H17 N O6 
331.32 
100(2) K 
1.54178 A 
Triclinic,  P-1 
a = 4.6972(4) A   alpha = 74.188(4) deg. 
b = 12.2452(8) A    beta = 84.703(5) deg. 
c = 13.2260(9) A   gamma = 82.708(4) deg. 
724.70(9) A^3 
2,  1.518 Mg/m^3 
0.976 mm^-1 
348 
0.15 x 0.05 x 0.04 mm 
3.48 to 65.06 deg. 
-5<=h<=4, -13<=k<=14, -15<=l<=15 
5709 / 2333 [R(int) = 0.0419] 
94.5 % 
Semi-empirical from equivalents 
0.9620 and 0.8674 
Full-matrix least-squares on F^2 
2333 / 0 / 223 
1.022 
R1 = 0.0488, wR2 = 0.1301 
R1 = 0.0703, wR2 = 0.1437 
0.453 and -0.310 e.A^-3 
 
Indexing was performed using APEX2 (Difference Vectors method). Data 
integration and reduction were performed using SaintPlus 6.01. Absorption 
correction was performed by the multi-scan method implemented in SADABS. 
Space groups were determined using XPREP implemented in APEX2. The 
	   109	  
structure was solved using SHELXS-97 and refined using SHELXL-97 contained 
in APEX2 and WinGX v1.70.01 packages. All non-hydrogen atoms were refined 
anisotropically. Hydrogen atoms were placed in geometrically calculated 
positions and included in the refinement process using a riding model. 
 
5.3. Experimental supporting Chapter 3 
 
Experiments with Aspergillus niger. For each condition, three 125 mL 
Erlenmeyer flasks containing 50 mL of PDB were inoculated with A. niger spores 
from an inoculating loop. The cultures were then shaken on a rotary shaker at 
ambient conditions for 24 h. After that incubation time, aliquots of sodium 
butyrate powder were added to achieve a final concentration of 10 µM into three 
cultures and 100 µM into three other cultures. A final three others were left 
untouched as controls. The nine cultures were then further incubated at ambient 
conditions for 6 more days. The resulting fermentations were then extracted 
3 times with dichloromethane to obtain the crude extract used in the experiments. 
 
Experiments with mangrove endophytes. For each condition, three 250 mL 
Erlenmeyer flasks containing 150 mL of SDB were inoculated with four small 
(4 cm2) plugs agar supporting the mycelial growth. The cultures were then 
shaken on a rotary shaker at ambient conditions for 48 h. After that incubation 
time, aliquots of sodium butyrate powder were added to achieve a final 
concentration of 100 µM into each culture. Three cultures were left untouched as 
controls. The resulting cultures were then further incubated at ambient conditions 
	   110	  
for 20 more days. The fermentations were then extracted 3 times with 
dichloromethane to obtain the crude extract used in the experiments. 
 
DNA extraction. The fungus was grown on a plate of SDA for 7 days. An area of 
1 cm2 of the fungal mat was cut and placed into a 1.5 mL Eppendorf tube with 
600 µL of PBS buffer and about 0.5 cm of 0.1 mm glass disruption beads. The 
tube was placed into a bead beater and pulsed for 1 m, three times, to lyse the 
cells. The tubes were centrifuged and the supernatant removed to a clean 
microfuge snap-cap tube. An aliquot (200 µL) of 1.6% sarkosyl and 25 µg of 
proteinase K were added, and incubated at 60 °C for 60 min. After incubation, 
800 µL of phenol/chloroform was added and the samples vortexed. The resulting 
emulsion was centrifuged for 5 min and the aqueous layer was removed and 
placed into a new tube. 500 µL of isopropanol and 100 µL of 3 M sodium acetate 
were then added to tubes before being mixed. Tubes were then placed at -80 °C 
for 2 h to allow DNA precipitation. The sample was then vortexed for 5 min and 
the supernatant was discarded. The DNA pellet was washed with 500 µL of 70% 
ethanol and resuspended in water in a refrigerator overnight. 
 
PCR parameters. DNA from the fungus was amplified in two PCR mixtures 
containing the following total amounts: 2 µL of DNA, 12.5 µL Taq DNA 
Polymerase, 6.5 µL of DI water, 2 µL of forward primer nu-SSU-0817-5’ 
(TTAGCATGGA ATAATRRAATAGGA) and either 2 µL of reverse primer nu-
SSU-1196-3’ (TCTGGACCTGGTGAGTTTCC) or nu-SSU-1536-3’ 
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(ATTGCAATGCYCTATCCCCA).21 All reagents were combined and heated at 
94 °C for 2.5 min. Thirty-five cycles of PCR were then performed by using 94 °C 
for 0 s, 56 °C for 10 s, and 72 °C for 30 s, followed by 72 °C for 2.5 min. 
 
Gel Step and isolation of DNA. 1% agarose gel was poured into a gel caster 
with 10 µL of 10 mg mL-1 solution of ethidium bromide. When the gel had 
solidified, it was placed into a gel electrophoresis apparatus filled with TAE 
buffer. An aliquot (25 µL) of the PCR sample mixtures were added to wells 
alongside 25 µL of a 1 kb DNA ladder. Samples were then run at 80 volts and 
400 mA for 30 min. The resulting gel was viewed under a UV lamp and the 
portions containing DNA were removed using a surgical blade. The DNA was 
then isolated and purified using a QIAquick Gel Extraction kit. 
 
Fungus Identification. The DNA was sent to Eurofins MWG Operon for 
sequencing. Upon receiving the results, they were compared to the BLAST 
database and the fungus was found to be 99% identical to Leucostoma 
persoonii. 
 
Experiments with L. persoonii. For each concentration experiment, three 
250 mL Erlenmeyer flasks containing 150 mL of SDB were inoculated with four 
small (4 cm2) plugs agar supporting the L. persoonii. The cultures were then 
shaken on a rotary shaker at ambient conditions for 48 h. After that incubation 
time, aliquots of 5-azacitydine and/or sodium butyrate powder were added to 
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achieve final concentrations of 1, 10, 50, 100 and 500 µM. The cultures were 
then further incubated at ambient conditions for 20 more days. The resulting 
fermentations were then extracted 3 x with dichloromethane to obtain the crude 
extract used in the experiments. For the time experiments, a similar approach 
was used, except that after the initial 48 h incubations, a final concentration of 
100 µM  of sodium butyrate and 50 µM of 5-azacitydine was achieved. Three 
controls were also fermented alongside with no epigenetic modifier. These 
cultures were grown for up to 6, 13 and 20 days longer and extracted in a similar 
fashion with dichloromethane. 
 
Cytosporone R. Colorless oil; [α]25D +0 (c 0.1, MeOH); UV/Vis (MeOH) 
λmax (ε): 269, 297; IR (thin film): 3237, 2928, 2855, 1706, 1589, 1467, 1371, 
1331, 1269, 1241, 1165, 1111 cm−1; For 1H  and 13C NMR please refer to Table 
3.6; HRESIMS m/z [M+Na]+ 391.1740 (calculated for C19H28O7Na, 391.1733). 
 
 
5.4. Experimental supporting Chapter 4 
 
All reactions that required dry/inert atmosphere were performed under dry argon 
gas using glassware that had been previously dried in a 180 °C oven overnight. 
Dry THF was distilled prior to use from sodium metal and benzophenone ketyl.  
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Step 1. 
 
The following method is representative for the preparation of compounds 4.14, 
4.26, 4.27 and 4.28. To a vessel containing 9 mL of CH2Cl2 was added        
3,4,5-trimethoxybenzoic acid (447 mg, 2.11 mmol), then the solution was stirred 
and cooled to 0 °C. Next, EDC (809 mg, 4.22 mmol) and HOBt (570 mg, 4.22 
mmol) were added. In a second vessel also containing 9 mL of CH2Cl2 was 
added L-valine methyl ester hydrochloride (500 mg, 3.17 mmol) and Et3N (0.588 
mL, 4.22 mmol) and stirred for 10 min. This second solution was then poured into 
the cooled benzoic acid suspension. The reaction was then warmed to room 
temperature (rt) and stirred for 24 h. The mixture was concentrated in vacuo and 
partitioned in EtOAc and water. The organic layer was washed with 1M HCl and 
saturated NaHCO3 and water. It was dried over MgSO4, filtered and loaded onto 
silica. The resulting mass was purified by normal phase MPLC on a silica column 
with a gradient starting from 100% hexanes to 100% EtOAc to afford 595.1 mg 
(87% yield) of 4.14. 
 
4.14. White crystals; [α]25D +0.410 (c 1.0, DCM); Mp = 130-132 °C; UV/Vis (DCM) 
λmax (ε): 262; IR (thin film): 1746, 1585, 1499, 1235, 1127, 1007 cm−1; 1H NMR 
R
R
R
N
H
O
CO2CH3
4.14: R = OCH3
4.26: R = F
4.27: R = CH3
4.28: R = H
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(500 MHz; CDCl3): δ 7.02 (s, 2H), 6.54 (d, J = 8.5, 1H), 4.76 (dd, J = 8.6, 5.0, 
1H), 3.91 (s, 6H), 3.88 (d, J = 0.6, 3H), 3.78 (s, 3H), 2.27 (dq, J = 12.4, 6.4, 1H), 
1.63 (d, J = 0.7, 1H), 1.00 (dd, J = 12.0, 6.9, 6H); 13C NMR (125 MHz; CDCl3): 
δ 172.9, 167.1, 153.4, 141.4, 129.7, 104.7, 61.1, 57.7, 56.54, 56.51, 52.4, 31.8, 
19.2, 18.20, 18.17. HRESIMS m/z [M+H]+ 326.1594 (calculated for C16H24NO6, 
326.1603). 
 
4.26. White amorphous solid; [α]25D +1.565 (c 1.0, DCM); UV/Vis (DCM) 
λmax (ε): 272; IR (thin film): 1748, 1514, 1439, 1369, 1212, 1048 cm−1; 1H NMR 
(500 MHz; CDCl3): δ 7.43 (t, J = 6.9, 2H), 6.98 (d, J = 8.3, 1H), 4.65 (dd, J = 8.5, 
5.4, 1H), 3.74 (s, 3H), 2.21 (dq, J = 13.0, 6.5, 1H), 0.94 (dd, J = 6.7, 4.2, 6H); 13C 
NMR (125 MHz; CDCl3): δ 172.6, 164.3 (d, J = 0.90), 152.0 (dd, J = 10.19, 3.52), 
150.0 (dd, J = 10.19, 3.52), 142.0 (dt, J = 257.57, 16.12), 129.9 (q, J = 5.44), 
111.9 (dd, J = 16.12, 5.44), 57.9, 52.3 (d, J = 2.30), 31.3, 18.9, 18.0. HRESIMS 
m/z [M+H]+ 290.0996 (calculated for C13H15NO3F3, 290.1004). 
 
4.27. White amorphous solid; [α]25D +0.103 (c 0.1, DCM); UV/Vis (DCM) 
λmax (ε): 277; IR (thin film): 3283, 2966, 1745, 1644, 1532, 1208 cm−1; 1H NMR 
(500 MHz; CDCl3): δ 7.18 (s, 1H), 6.97 (s, 1H), 6.27 (d, J = 8.4, 1H), 4.74 
(dd, J = 8.9, 4.8, 1H), 3.75 (s, 3H), 2.38 (s, 3H), 2.22 (s, 6H), 1.01 (d, J = 6.9, 
3H), 0.94 (d, J = 6.9, 3H); 13C NMR (125 MHz; CDCl3): δ 172.6, 169.8, 138.7, 
133.9, 133.46, 133.31, 132.4, 128.1, 57.2, 52.14, 52.12, 31.4, 19.51, 19.39, 19.1, 
17.9. HRESIMS m/z [M+H]+ 278.1743 (calculated for C16H24NO3, 278.1756). 
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4.28. White amorphous solid; [α]25D +0.156 (c 1.0, DCM); UV/Vis (DCM) 
λmax (ε): 267; IR (thin film): 2966, 1745, 1648, 1532, 1491, 1212 cm−1; 1H NMR 
(500 MHz; CDCl3): δ 7.80 (d, J = 7.0, 2H), 7.51 (t, J = 7.3, 1H), 7.44 (t, J = 7.5, 
2H), 6.65 (d, J = 7.1, 1H), 4.78 (dd, J = 8.6, 4.9, 1H), 3.77 (s, 3H), 2.27 
(dq, J = 12.3, 6.4, 1H), 1.00 (dd, J = 11.8, 6.9, 6H); 13C NMR (125 MHz; CDCl3): 
δ 172.8, 167.5, 134.4, 131.9, 128.8, 127.2, 57.6, 52.44, 52.42, 31.8, 19.2, 18.2. 
HRESIMS m/z [M+H]+ 236.1291 (calculated for C13H18NO3, 236.1287). 
 
Step 2. 
 
The following method is representative for the preparation of compounds 4.15, 
4.29, 4.30 and 4.31. To a dry reaction vessel, we added 4.14 (582.6 mg, 
1.79 mmol) and dry THF (25 mL), then cooled it to 0 °C while stirring. Next, we 
added LiBH4 (1.79 mL of a 2 M solution in THF, 3.58 mmol) dropwise. The 
solution was warmed to rt and stirred for 20 h. Quenched reaction with 2 M HCl 
and then conventrated in vacuo. Partitioned with ETOAc and water. The aqueous 
partition was extracted two more times with EtOAc and the organic extracts were 
combined. Washed with 1M NaOH, then saturated NaCl and dried with MgSO4. 
R
R
R
N
H
OH
4.15: R = OCH3
4.29: R = F
4.30: R = CH3
4.31: R = H
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The resulting organic layer was filtered and then loaded onto silica. The resulting 
mass was purified by normal phase MPLC on a silica column with a gradient 
from 100% hexanes to 100% EtOAc to afford 353.6 mg (67% yield) of 4.15. 
 
4.15. White crystals; [α]25D -0,181 (c 1.0, DCM); Mp = 163-165 °C; UV/Vis (DCM) 
λmax (ε): 261; IR (thin film): 3294, 1540, 1585, 1417, 1238, 1134 cm−1; 1H NMR 
(500 MHz; CDCl3): δ 6.98 (s, 2H), 6.34 (d, J = 8.3, 1H), 3.88 (s, 6H), 3.86 (s, 3H), 
3.79 (d, J = 4.0, 2H), 2.78 (s, 1H), 2.01 (dq, J = 13.9, 6.9, 1H), 1.01 (dd, J = 9.0, 
6.8, 6H); 13C NMR (125 MHz; CDCl3): δ 168.1, 153.2, 141.0, 130.0, 104.5, 63.8, 
60.9, 57.6, 56.4, 29.2, 19.6, 19.14, 19.11. HRESIMS m/z [M+H]+ 298.1664 
(calculated for C15H24NO5, 298.1654). 
 
4.29. White amorphous solid; [α]25D -0.430 (c 1.0, DCM); UV/Vis (DCM) 
λmax (ε): 277; IR (thin film): 1622, 1525, 1439, 1372, 1238, 1052 cm−1; 1H NMR 
(500 MHz; CDCl3): δ 7.43 (t, J = 6.9, 2H), 6.40 (d, J = 7.8, 1H), 3.91 (tt, J = 8.2, 
4.1, 1H), 3.78 (d, J = 4.3, 2H), 2.40 (s, 1H), 1.99 (dq, J = 13.8, 6.9, 1H), 1.00 
(dd, J = 12.8, 6.8, 6H); 13C NMR (125 MHz; CDCl3): δ 164.9, 152.1 (t, J = 9.46), 
150.1 (d, J = 10.46), 142.9 (d, J = 15.75), 130.5 (t, J = 4.78), 111.7 
(dd, J = 17.36, 5.06), 63.2, 57.5, 29.2, 19.5, 19.1. HRESIMS m/z [M+H]+ 
262.1052 (calculated for C12H15NO2F3, 262.1055). 
 
4.30. White amorphous solid; [α]25D -1.363 (c 1.0, DCM); UV/Vis (DCM) 
λmax (ε): 279; IR (thin film): 3275, 2959, 1638, 1536, 1451, 1078 cm−1; 1H NMR 
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(500 MHz; CDCl3): δ 7.11 (s, 1H), 6.95 (s, 1H), 6.08 (d, J = 8.4, 1H), 3.88-3.83 
(m, 1H), 3.74-3.66 (m, 2H), 2.34 (s, 3H), 2.20 (d, J = 11.7, 6H), 1.93 
(dq, J = 13.7, 6.8, 1H), 0.98 (dd, J = 8.2, 6.9, 7H); 13C NMR (125 MHz; CDCl3): 
δ 171.2, 138.5, 133.86, 133.80, 133.1, 132.3, 127.9, 63.8, 57.2, 29.1, 19.60, 
19.51, 19.32, 19.08, 18.89. HRESIMS m/z [M+H]+ 250.1810 (calculated for 
C15H24NO2, 250.1807). 
 
4.31. White amorphous solid; [α]25D -2.750 (c 1.0, DCM); UV/Vis (DCM) 
λmax (ε): 269; IR (thin film): 2959, 1648, 1458, 1350, 1130, 1000 cm−1; 1H NMR 
(500 MHz; CDCl3): δ 7.59 (d, J = 7.2, 2H), 7.27 (t, J = 7.4, 1H), 7.16 (t, 
J = 7.6, 2H), 7.00 (d, J = 8.8, 1H), 4.22 (s, 1H), 3.72 (td, J = 8.0, 4.1, 1H), 3.61-
3.53 (m, 2H), 1.86 (dq, J = 13.9, 6.9, 1H), 0.82 (t, J = 6.9, 6H); 13C NMR 
(125 MHz; CDCl3): δ 168.4, 134.5, 131.4, 128.4, 127.0, 105.0, 62.7, 57.3, 29.0, 
19.5, 19.2. HRESIMS m/z [M+H]+ 208.1331 (calculated for C12H18NO2, 208.1337) 
 
Step 3. 
 
R
R
R
O
N
4.16: R = OCH3
4.32: R = F
4.33: R = CH3
4.34: R = H
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The following method is representative for the preparation of compounds 4.16, 
4.32, 4.33 and 4.34. To a vessel containing 2.5 mL of CH2Cl2 was added 4.15 
(150 mg, 0.505 mmol) and then the stirring solution was cooled to 0 °C. Et3N 
(2.23 mL, 1.60 mmol) was added to the solution and then MsCl (0.0783 mL, 
1.01 mmol) dropwise. The reaction was warmed to rt and stirred for 16 h. The 
solution was concentrated in vacuo and then partitioned with EtOAc and water. 
The aqueous partition was extracted two more times with EtOAc and then the 
organic extracts were combined. Washed with saturated NaCl and dried with 
MgSO4. The resulting organic layer was filtered and then loaded onto silica. The 
resulting mass was purified by normal phase MPLC on a silica column with a 
gradient starting from 100% hexanes to 100% EtOAc to afford 244.9 mg (87% 
yield) of 4.16. 
 
4.16. Yellow oil; [α]25D -0.238 (c 1.0, DCM); UV/Vis (DCM) λmax (ε): 267; IR (thin 
film): 1592, 1510, 1465, 1421, 1369, 1134 cm−1; 1H NMR (500 MHz; CDCl3): 
δ 6.89 (s, 2H), 4.02 (q, J = 8.4, 1H), 3.73 (dt, J = 14.5, 7.1, 2H), 3.55 (s, 6H), 2.76 
(s, 1H), 1.67 (s, 1H), 1.48 (dd, J = 12.8, 6.4, 1H), 0.88 (t, J = 7.1, 1H), 0.68 
(d, J = 6.7, 3H), 0.57 (t, J = 4.6, 3H); 13C NMR (125 MHz; CDCl3): δ 162.1, 152.3, 
140.0, 122.5, 104.8, 72.0, 69.4, 59.9, 55.3, 32.2, 18.2, 17.4. HRESIMS 
m/z [M+H]+ 280.1537 (calculated for C15H22NO4, 280.1549). 
 
4.32. White amorphous solid; [α]25D -0.004 (c 0.1, DCM); UV/Vis (MeOH) 
λmax (ε): 227, 248; IR (thin film): 2962, 1532, 1443, 1387, 1052, 985 cm−1; 
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1H NMR (500 MHz; CDCl3):δ 7.58 (dd, J = 8.1, 6.8, 2H), 4.42 (dd, J = 9.3, 8.1, 
1H), 4.14 (t, J = 8.1, 1H), 4.09 (dd, J = 9.2, 6.3, 1H), 1.83 (dq, J = 13.3, 6.7, 1H), 
1.01 (d, J = 6.7, 3H), 0.92 (d, J = 6.8, 3H); 13C NMR (125 MHz; CDCl3): δ 160.7 
(dd, J = 4.16, 2.26), 151.9 (dd, J = 10.33, 3.76), 149.9 (dd, J = 10.33, 3.76), 
142.8, 140.7, 112.7 (dd, J = 17.43, 5.57), 72.9, 70.8, 32.8, 18.8, 18.1. HRESIMS 
m/z [M+H]+ 244.0944 (calculated for C12H13NOF3, 244.0949). 
 
4.33. White amorphous solid; [α]25D -1.184 (c 0.1, DCM); UV/Vis (DCM) 
λmax (ε): 285; IR (thin film): 2959, 1648, 1458, 1350, 1130, 1000 cm−1; 1H NMR 
(500 MHz; CDCl3): δ 7.57 (s, 1H), 7.00 (s, 1H), 4.33 (dd, J = 9.0, 7.6, 1H), 4.14-
4.06 (m, 2H), 2.52 (s, 3H), 2.24 (d, J = 3.5, 6H), 1.85 (dt, J = 12.9, 6.5, 1H), 1.03 
(d, J = 6.8, 3H), 0.95 (d, J = 6.8, 3H); 13C NMR (125 MHz; CDCl3): δ 164.0, 
139.1, 135.9, 133.6, 132.5, 130.8, 124.7, 72.8, 69.2, 32.9, 21.1, 19.6, 19.0, 18.8, 
18.1. HRESIMS m/z [M+H]+ 232.1697 (calculated for C15H22NO, 232.1701). 
 
4.34. White amorphous solid; [α]25D -0.305 (c 0.1, DCM); UV/Vis (DCM) 
λmax (ε): 270; IR (thin film): 3316, 2962, 1640, 1544, 1078, 698 cm−1; 1H NMR 
(500 MHz; CDCl3): δ 7.70 (d, J = 7.4, 2H), 7.40 (t, J = 7.4, 1H), 7.29 (t, J = 7.7, 
2H), 6.86 (d, J = 8.7, 1H), 3.95 (s, 1H), 3.84 (tt, J = 8.2, 4.1, 1H), 3.72-3.65 
(m, 2H), 1.96 (dq, J = 13.9, 6.9, 1H), 0.93 (t, J = 7.6, 6H); 13C NMR (125 MHz; 
CDCl3): δ 168.6, 134.7, 131.6, 128.6, 127.2, 105.2, 63.2, 57.5, 29.3, 19.8, 19.3. 
HRESIMS m/z [M+H]+ 190.1222 (calculated for C12H16NO, 190.1232). 
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Step 4. 
 
The following method is representative for the preparation of compounds 4.18, 
4.35, 4.36, 4.37, 4.44, 4.45, and 4.46. To a dry reaction vessel, added 4.16 
(50.0 mg, 0.179 mmol) and dry THF (1.5 mL), then cooled to -78 °C. Next, added 
n-BuLi (0.134 mL of a 1.6 M solution in hexanes, 0.215 mmol) dropwise and 
stirred for 30 minutes. While the reaction was still at -78 °C, added n-octanal 
(0.034 mL, 0.215 mmol) dropwise. After 2 h, poured water into vessel and 
allowed to stir for 10 min. Partitioned reaction solution with Et2O, and then 
washed organic extract in saturated NaCl. Dried over MgSO4, filtered and loaded 
onto silica. The resulting mass was purified by normal phase MPLC on a silica 
column with a gradient starting from 100% hexanes to 100% EtOAc to afford 
37.9 mg (52% yield) of 4.18. 
 
4.18. Yellow oil; UV/Vis (DCM) λmax (ε): 254, 301; IR (thin film): 2929, 1689, 1480, 
1350, 1112, 974 cm−1; 1H NMR (500 MHz; CDCl3): δ 7.20 (s, 1H), 5.49 
(dd, J = 7.6, 3.1, 1H), 3.98 (d, J = 2.6, 7H), 3.94 (s, 3H), 3.79 (t, J = 5.2, 2H), 2.67 
(s, 1H), 2.15-2.09 (m, 1H), 1.95-1.91 (m, 1H), 1.67-1.61 (m, 1H), 1.44-1.28 
R1
R1
R1
O
N
OH
R2
H
4.18: R1 = OCH3, R2 = (CH2)6CH3
4.35: R1 = F, R2 = (CH2)6CH3
4.36: R1 = CH3, R2 = (CH2)6CH3
4.37: R1 = H, R2 = (CH2)6CH3
4.44: R1 = OCH3, R2 = CH3
4.45: R1 = OCH3, R2 = C6H5
4.46: R1 = OCH3, R2 = (CH2)4CH3
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(m, 10H), 1.02 (d, J = 6.7, 3H), 0.96 (d, J = 6.8, 3H), 0.93 (t, J = 6.9, 3H); 13C 
NMR (125 MHz; CDCl3): δ 169.1, 155.2, 147.6, 144.6, 131.8, 126.2, 101.2, 82.4, 
64.8, 63.9, 61.1, 60.78, 56.6, 34.2, 31.9, 30.5, 29.5, 29.3, 24.9, 22.7, 19.9, 19.56, 
14.2. HRESIMS m/z [M+H]+ 408.2739 (calculated for C23H38NO5, 408.2750). 
 
4.35. Yellow oil; UV/Vis (MeOH) λmax (ε): 241, 283; IR (thin film): 2929, 1696, 
1510, 1484, 1383, 1074 cm−1; Inseparable isomers. HRESIMS m/z [M+H]+ 
372.2148 (calculated for C20H29NO2F3, 372.2150). 
 
4.36. Yellow oil; UV/Vis (MeOH) λmax (ε): 244, 287; IR (thin film): 2929, 2858, 
1648, 1462, 1361, 1138 cm−1; Inseparable isomers. HRESIMS m/z [M+H]+ 
360.2911 (calculated for C23H38NO2, 360.2903). 
 
4.37. Yellow oil; UV/Vis (MeOH) λmax (ε): 242, 284; IR (thin film): 2959, 2929, 
1689, 1469, 1067, 1041 cm−1; Inseparable isomers. HRESIMS m/z [M+H]+ 
318.2446 (calculated for C20H32NO2, 318.2433). 
 
4.44. Yellow oil; UV/Vis (DCM) λmax (ε): 255, 300; IR (thin film): 2955, 1689, 1484, 
1424, 1354, 1119 cm−1; 1H NMR (500 MHz; CDCl3): δ 7.30 (s, 1H), 5.29 
(q, J = 6.3, 1H), 3.98 (s, 3H), 3.92 (d, J = 7.1, 6H), 3.81 (s, 2H), 1.85 
(dd, J = 13.3, 6.5, 1H), 1.52 (d, J = 6.5, 3H), 1.00 (d, J = 6.7, 3H), 0.93 
(d, J = 6.7, 3H); 13C NMR (125 MHz; CDCl3): δ 160.9, 154.9, 147.1, 144.1, 132.7, 
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125.6, 101.3, 64.8, 64.0, 60.9, 60.6, 56.4, 30.9, 20.5, 19.7, 19.5. 
HRESIMS m/z [M+H]+ 324.1825 (calculated for C17H26NO5, 324.1811). 
 
4.45. Yellow oil; UV/Vis (MeOH) λmax (ε): 221.263; IR (thin film): 2959, 1689, 
1480, 1424 1350, 1112 cm−1; Inseparable isomers. HRESIMS m/z [M+H]+ 
386.1982 (calculated for C22H28NO5, 386.1967). 
 
4.46. Yellow oil; UV/Vis (DCM) λmax (ε): 255, 301; IR (thin film): 2959, 2877, 1689, 
1480, 1354, 1112 cm−1; 1H NMR (500 MHz; CDCl3): δ 7.13 (s, 1H), 5.44 
(dd, J = 7.5, 3.0, 1H), 3.92 (d, J = 2.6, 6H), 3.88 (s, 3H), 3.74-3.71 (m, 2H), 2.09-
2.04 (m, 1H), 1.87 (dq, J = 13.3, 6.6, 1H), 1.65-1.58 (m, 1H), 1.38-1.26 (m, 8H), 
0.97 (d, J = 6.7, 3H), 0.90 (d, J = 6.8, 3H), 0.87 (t, J = 6.5, 3H); 13C NMR (125 
MHz; CDCl3): δ 160.6, 155.1, 147.5, 144.5, 131.7, 126.1, 101.1, 82.2, 64.7, 63.8, 
61.0, 60.6, 56.4, 34.0, 31.6, 30.4, 24.4, 22.5, 19.7, 19.4, 14.0. 
HRESIMS m/z [M+H]+ 380.2419 (calculated for C21H34NO5, 380.2437). 
 
 
Step 5. 
 
4.19: R1 = OCH3, R2 = (CH2)6CH3
4.21: R1 = F, R2 = (CH2)6CH3
4.23: R1 = CH3, R2 = (CH2)6CH3
4.25: R1 = H, R2 = (CH2)6CH3
4.47: R1 = OCH3, R2 = CH3
4.48: R1 = OCH3, R2 = C6H5
4.49: R1 = OCH3, R2 = (CH2)4CH3
R1
R1
R1
O
O
R2
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The following method is representative for the preparation of compounds 4.19, 
4.21, 4.23, 4.25, 4.47, 4.48, and 4.49. To a vessel containing 4.18 (25 mg, 
0.061 mmol) and THF (0.100 mL) was added 3 M HCl (0.93 mL). The solution 
was refluxed at 110 °C for 30 min. After cooling, the reaction was partitioned in 
CH2Cl2. The aqueous layer was extracted two more times with CH2Cl2 and the 
combined organic layers were dried over MgSO4, then filtered and loaded onto 
silica. The resulting mass was purified by normal phase MPLC on a silica column 
with a gradient starting from 100% hexanes to 100% EtOAc to afford 15.8 mg 
(80% yield) of 4.19.  
 
4.19. White amorphous solid; UV/Vis (DCM) λmax (ε): 258, 299; IR (thin film): 
2929, 2858, 1763, 1480, 1346, 1108 cm−1; 1H NMR (500 MHz; CDCl3): δ 7.08 (s, 
1H), 5.42 (d, J = 5.4, 1H), 3.94 (s, 3H), 3.89 (d, J = 11.7, 6H), 2.17-2.14 (m, 1H), 
1.69-1.65 (m, 1H), 1.40-1.22 (m, 10H), 0.83 (d, J = 6.9, 3H); 13C NMR (125 MHz; 
CDCl3): δ 170.5, 155.5, 147.6, 146.8, 135.4, 121.4, 102.5, 80.1, 61.0, 60.8, 56.3, 
33.4, 31.7, 29.22, 29.04, 24.7, 22.6, 14.0. HRESIMS m/z [M+H]+ 323.1853 
(calculated for C18H27O5, 323.1859). 
 
4.21. White amorphous solid; UV/Vis (MeOH) λmax (ε): 226, 277; IR (thin film): 
2929, 1782, 1510, 1488, 1369, 1078 cm−1; 1H NMR (500 MHz; CDCl3): δ 7.54 
(ddd, J = 7.4, 5.8, 1.6, 1H), 5.59 (dd, J = 8.0, 2.9, 1H), 2.23-2.16 (m, 1H), 1.79 
(dddd, J = 14.4, 10.2, 8.2, 4.3, 1H), 1.49-1.44 (m, 1H), 1.44-1.35 (m, 2H), 1.33-
1.23 (m, 8H), 0.88 (t, J = 7.0, 3H); 13C NMR (125 MHz; CDCl3): δ 167.6 
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(t, J = 2.54), 152.5 (m), 145.5 (m), 143.9 (m), 132.9 (dd, J = 14.75), 122.2 
(dt, J = 8.33, 3.84), 109.8 (dd, J = 4.09, 1.35), 109.7 (dd, J = 4.09, 1.35), 79.1 
(t, J = 2.42), 33.5, 31.6, 29.07, 28.96, 24.6, 22.6, 14.0. HRESIMS m/z [M+H]+ 
287.1267 (calculated for C15H18O2F3, 287.1259). 
 
4.23. White amorphous solid; UV/Vis (DCM) λmax (ε): 244, 288; IR (thin film): 
2929, 2858, 1726, 1622, 1462, 1235 cm−1; 1H NMR (500 MHz; CDCl3): δ 7.83 
(s, 1H), 6.98 (s, 1H), 4.46-4.45 (m, 1H), 2.90-2.79 (m, 2H), 2.28 (d, J = 10.7, 7H), 
1.86-1.81 (m, 1H), 1.70-1.65 (m, 2H), 1.55-1.53 (m, 1H), 1.44 (dd, J = 2.8, 1.4, 
1H), 1.30-1.27 (m, 10H), 0.87 (d, J = 7.0, 3H); 13C NMR (125 MHz; CDCl3): 
δ 166.1, 143.4, 136.7, 136.1, 130.9, 128.4, 122.7, 78.8, 35.0, 32.7, 31.8, 29.4, 
29.1, 24.9, 22.6, 20.1, 19.3, 14.1. HRESIMS m/z [M+H]+ 275.2008 (calculated for 
C18H27O2, 275.2011). 
 
4.25. Yellow oil; UV/Vis (MeOH) λmax (ε): 227, 274; IR (thin film): 2929, 2858, 
1767, 1469, 1290, 1067 cm−1; 1H NMR (500 MHz; CDCl3): δ 7.87 (d, J = 7.7, 1H), 
7.65 (td, J = 7.5, 1.0, 1H), 7.50 (t, J = 7.5, 1H), 7.43 (dd, J = 7.7, 0.7, 1H), 5.46 
(dd, J = 7.9, 4.1, 1H), 2.02 (dddd, J = 14.3, 10.1, 5.8, 4.2, 1H), 1.74 
(dddd, J = 14.4, 9.9, 8.0, 4.8, 1H), 1.54-1.39 (m, 2H), 1.38-1.23 (m, 8H), 0.86 
(t, J = 7.0, 3H); 13C NMR (125 MHz; CDCl3): δ 170.7, 150.1, 133.9, 129.0, 125.6, 
121.7, 81.4, 34.8, 31.7, 29.3, 29.0, 24.8, 22.6, 14.0. HRESIMS m/z [M+H]+ 
265.1052 (calculated for C14H17O5, 265.1076). 
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4.47. Yellow oil; UV/Vis (DCM) λmax (ε): 260, 298; IR (thin film): 1763, 1484, 1424, 
1343, 1123, 1048 cm−1; 1H NMR (500 MHz; CDCl3): δ 7.12 (s, 1H), 5.51 
(q, J = 6.6, 1H), 3.98 (s, 3H), 3.93 (d, J = 13.1, 6H), 1.64 (d, J = 6.6, 1H), 1.32-
1.24 (m, 2H), 0.88 (t, J = 6.5, 3H); 13C NMR (125 MHz; CDCl3): δ 170.3, 155.6, 
147.6, 146.9, 136.7, 121.1, 102.6, 60.9, 56.4, 34.1, 31.6, 22.3, 19.7, 14.1. 
HRESIMS m/z [M+H]+ 239.0931 (calculated for C12H15O5, 239.0920). 
 
4.48. Yellow oil; UV/Vis (DCM) λmax (ε): 261, 300; IR (thin film): 1771, 1480, 1346, 
1112, 1033, 978 cm−1; 1H NMR (500 MHz; CDCl3): δ 7.34 (t, J = 2.5, 4H), 7.25 
(t, J = 2.9, 2H), 7.19-7.19 (m, 1H), 6.33 (s, 1H), 3.93-3.89 (m, 6H), 3.44-3.44 
(m, 3H); 13C NMR (125 MHz; CDCl3): δ 170.6, 156.1, 148.1, 147.6, 136.5, 135.8, 
129.3, 128.8, 127.5, 121.0, 102.8, 81.4, 61.2, 60.5, 56.6. HRESIMS m/z [M+H]+ 
301.1059 (calculated for C17H17O5, 301.1076). 
 
4.49. Yellow oil; UV/Vis (DCM) λmax (ε): 256, 301; IR (thin film): 2936, 1767, 1480, 
1350, 1108, 1041 cm−1; 1H NMR (500 MHz; CDCl3): δ 7.09 (s, 1H), 5.43 
(dd, J = 7.9, 3.0, 1H), 3.95 (s, 3H), 3.92 (s, 3H), 3.89 (s, 3H), 2.20-2.13 (m, 1H), 
1.71-1.64 (m, 1H), 1.41-1.23 (m, 10H), 0.85 (t, J = 7.0, 4H); 13C NMR (125 MHz; 
CDCl3): δ 170.6, 155.5, 147.6, 146.8, 135.4, 121.4, 102.5, 80.2, 61.1, 60.8, 56.4, 
33.4, 31.5, 24.4, 22.4, 14.0. HRESIMS m/z [M+H]+ 295.1538 (calculated for 
C16H23O5, 295.1546). 
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Step 6. 
 
The following method is representative for the preparation of compounds 4.39, 
4.41, 4.43 and cytosporone E. Added 4.19 (20.0 mg, 0.062 mmol) into a dry 
vessel under argon containing DMF (1.0 mL). Added iodocyclohexane 
(0.122 mL, 0.93 mmol) and refluxed for 4 h. Allowed mixture to cool to rt and then 
added water (5 mL). Partitioned with EtOAc and then washed the organic layer 
with NaHSO3. Dried over MgSO4, filtered and loaded onto silica. The resulting 
mass was purified by normal phase MPLC on a silica column with a gradient 
starting from 100% hexanes to 100% EtOAc to afford 16.3 mg (94% yield) of 
cytosporone E. 
 
4.39. Yellow oil; UV/Vis (MeOH) λmax (ε): 224, 278; IR (thin film): 3270, 1629, 
1484, 1346, 1045 cm−1; 1H NMR (500 MHz; CDCl3): δ 6.79 (s, 1H), 5.53-5.46 
(m, 2H), 2.67 (s, 1H), 1.60 (d, J = 6.5, 6H); 13C NMR (125 MHz; CDCl3): δ 176.4, 
151.2, 143.8, 143.6, 135.1, 119.3, 105.5, 80.6, 22.2. HRESIMS m/z [M+H]+ 
197.0442 (calculated for C9H9O5, 197.0450). 
 
HO
HO
OH
O
O
R
4.39: R = CH3 
4.41: R = C6H5
4.43: R = (CH2)4CH3
Cytosporone E: R = (CH2)4CH3
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4.41. Yellow oil; UV/Vis (MeOH) λmax (ε): 277; IR (thin film): 3298, 1737, 1655, 
1376, 1309, 1074 cm−1; 1H NMR (500 MHz; CDCl3): (REDO); 13C NMR 
(125 MHz; CDCl3): (REDO). HRESIMS m/z [M+H]+ 259.0623 (calculated for 
C14H11O5, 259.0607). 
 
4.43. Yellow oil; UV/Vis (DCM) λmax (ε): 262; IR (thin film): 3193, 2929, 1726, 
1335, 1074, 1011 cm−1; 1H NMR (500 MHz; CDCl3): δ 6.97 (s, 1H), 5.42 
(d, J = 7.3, 1H), 2.24-2.17 (m, 1H), 1.69-1.65 (m, 1H), 1.40-1.35 (m, 2H), 1.25 
(d, J = 16.8, 4H), 0.84 (s, 3H); 13C NMR (125 MHz; CDCl3): δ 171.8, 146.6, 
138.9, 137.7, 129.7, 117.5, 103.3, 80.4, 33.0, 31.5, 24.4, 22.5, 14.0. HRESIMS 
m/z [M+H]+ 253.1071 (calculated for C13H17O5, 253.1076). 
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Appendix A. NMR data supporting Chapter 2 
 
 
Figure A.1. 1H and 13C NMR Spectra of macrolactin A (2.2), 500 MHz and 125 MHz, CDCl3 
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Figure A.2. COSY NMR Spectrum of macrolactin A (2.2), 500 MHz, CDCl3 
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Figure A.3. HSQC NMR Spectrum of macrolactin A (2.2), 500 MHz, CDCl3 
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Figure A.4. HMBC NMR Spectrum of macrolactin A (2.2), 500 MHz, CDCl3 
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Figure A.5. 1H and 13C NMR Spectra of Sch 54796 (2.3), 500 MHz and 125 MHz, DMSO-d6 
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Figure A.6. COSY NMR Spectrum of Sch 54796 (2.3), 500 MHz, DMSO-d6 
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Figure A.7. HSQC NMR Spectrum of Sch 54796 (2.3), 500 MHz, DMSO-d6 
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Figure A.8. HMBC NMR Spectrum of Sch 54796 (2.3), 500 MHz, DMSO-d6 
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Figure A.9. 1H and 13C NMR Spectra of chaetomin (2.4), 500 MHz and 125 MHz, CDCl3 
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Figure A.10. 1H and 13C NMR Spectra of beauvericin (2.5), 500 MHz and 125 MHz, CDCl3 
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Figure A.11. 1H and 13C NMR Spectra of roquefortine C (2.7), 500 MHz and 125 MHz, CDCl3 
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Appendix B. NMR data supporting Chapter 3 
 
 
Figure B.1. 1H and 13C NMR Spectra of cytosporone A (3.11), 500 MHz and 125 MHz, CD3OD 
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Figure B.2. 1H and 13C NMR Spectra of cytosporone B (3.12), 500 MHz and 125 MHz, CD3OD 
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Figure B.3. 1H and 13C NMR Spectra of cytosporone C (3.13), 500 MHz and 125 MHz, CD3OD 
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Figure B.4. 1H and 13C NMR Spectra of cytosporone E (3.14), 500 MHz and 125 MHz, CD3OD 
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Figure B.5. 1H and 13C NMR Spectra of comazaphilone D (3.15), 500 MHz and 125 MHz, CDCl3 
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Figure B.6. 1H and 13C NMR Spectra of integracin A (3.16), 500 MHz and 125 MHz, CDCl3 
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Figure B.7. 1H and 13C NMR Spectra of integracin B (3.17), 500 MHz and 125 MHz, CDCl3 
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Figure B.8. 1H and 13C NMR Spectra of cytosporone R (3.18), 500 MHz and 125 MHz, CD3OD 
	   148	  
 
Figure B.9. COSY NMR Spectrum of cytosporone R (3.18), 500 MHz, CD3OD 
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Figure B.10. HSQC NMR Spectrum of cytosporone R (3.18), 500 MHz, CD3OD 
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Figure B.11. HMBC NMR Spectrum of cytosporone R (3.18), 500 MHz, CD3OD 
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Appendix C. NMR data supporting Chapter 4 
 
 
Figure C.1. 1H and 13C NMR Spectra of 4.14, 500 MHz and 125 MHz, CDCl3 
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Figure C.2. 1H and 13C NMR Spectra of 4.15, 500 MHz and 125 MHz, CDCl3 
	   153	  
 
Figure C.3. 1H and 13C NMR Spectra of 4.16, 500 MHz and 125 MHz, CDCl3 
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Figure C.4. 1H and 13C NMR Spectra of 4.17, 500 MHz and 125 MHz, CDCl3 
 
	   155	  
 
Figure C.5. 1H and 13C NMR Spectra of 4.19, 500 MHz and 125 MHz, CDCl3 
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Figure C.6. 1H and 13C NMR Spectra of 4.21, 500 MHz and 125 MHz, CDCl3 
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Figure C.7. 1H and 13C NMR Spectra of 4.23, 500 MHz and 125 MHz, CDCl3 
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Figure C.8. 1H and 13C NMR Spectra of 4.25, 500 MHz and 125 MHz, CDCl3 
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Figure C.9. 1H and 13C NMR Spectra of 4.26, 500 MHz and 125 MHz, CDCl3 
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Figure C.10. 1H and 13C NMR Spectra of 4.27, 500 MHz and 125 MHz, CDCl3 
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Figure C.11. 1H and 13C NMR Spectra of 4.28, 500 MHz and 125 MHz, CDCl3 
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Figure C.12. 1H and 13C NMR Spectra of 4.29, 500 MHz and 125 MHz, CDCl3 
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Figure C.13. 1H and 13C NMR Spectra of 4.30, 500 MHz and 125 MHz, CDCl3 
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Figure C.14. 1H and 13C NMR Spectra of 4.31, 500 MHz and 125 MHz, CDCl3 
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Figure C.15. 1H and 13C NMR Spectra of 4.32, 500 MHz and 125 MHz, CDCl3 
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Figure C.16. 1H and 13C NMR Spectra of 4.33, 500 MHz and 125 MHz, CDCl3 
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Figure C.17. 1H and 13C NMR Spectra of 4.34, 500 MHz and 125 MHz, CDCl3 
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Figure C.18. 1H and 13C NMR Spectra of 4.39, 500 MHz and 125 MHz, CDCl3 
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Figure C.19. 1H and 13C NMR Spectra of 4.41, 500 MHz and 125 MHz, CDCl3 
	   170	  
 
Figure C.20. 1H and 13C NMR Spectra of 4.43, 500 MHz and 125 MHz, CDCl3 
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Figure C.21. 1H and 13C NMR Spectra of 4.44, 500 MHz and 125 MHz, CDCl3 
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Figure C.22. 1H and 13C NMR Spectra of 4.46, 500 MHz and 125 MHz, CDCl3 
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Figure C.23. 1H and 13C NMR Spectra of 4.47, 500 MHz and 125 MHz, CDCl3 
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Figure C.24. 1H and 13C NMR Spectra of 4.48, 500 MHz and 125 MHz, CDCl3 
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Figure C.25. 1H and 13C NMR Spectra of 4.49, 500 MHz and 125 MHz, CDCl3 
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Permissions for Figure 1.5 
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Permission for Figure 1.6 
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Permission for Figures 1.7-1.8 
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2. No changes may be made to the McGraw-Hill Material without the prior written 
consent of McGraw-Hill. 
 
3. Licensee will provide to McGraw-Hill the URL and password for the web site in 
which the McGraw-Hill Material appears (if applicable). 
 
4. McGraw-Hill makes no representations or warranties as to the accuracy of any 
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arising out of or in connection with the McGraw-Hill Material, even if McGraw-Hill 
has been advised of the possibility of such damages.  All persons provided with the 
McGraw-Hill Material must be provided with written notice of this disclaimer and 
limitation liability, either in an end-user license and/or with an on-screen notice that is 
visible each time the end-user initiates access to the McGraw-Hill Material. 
 
5. A credit to McGraw-Hill shall be visible each time the end-user initiates access to any 
screen or page containing any of the McGraw-Hill Material.  Such credit shall include 
the title and author of the work and a copyright notice in the name of The McGraw-
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6. The permission fee of $0.00 must be received by The McGraw-Hill Companies, and 
MUST BE ACCOMPANIED BY A SIGNED COPY OF THIS AGREEMENT.  A 
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Permissions Department, The McGraw-Hill Companies, Two Penn Plaza, NY, NY 
10121-2298.  Please include the invoice number indicated at the top of this form on 
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7. This permission does not allow the use of any material, including but not limited to 
text, quotes, excerpts, prologues, worksheets, activities, boxes questionnaires, 
exhibits, poems, artwork, figures, diagrams, cartoons, drawings, tables, digital images, 
music, songs, lyrics, readings, articles, cases, charts, maps, solutions/answer keys, 
testbank/questions, photographs, charts, instruments, surveys and other illustrations, 
government work or material, which appears in a McGraw-Hill Companies' work 
copyrighted in or credited to the name of any person or entity other than The 
McGraw-Hill Companies.  Should you desire permission to use such material, you 
must seek permission directly from the owner of that material, and if you use such 
material you agree to indemnify The McGraw-Hill Companies against any claim from 
the owners of that material. 
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written notice to Licensee if Licensee is in material breach of this Agreement. 
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